KR20080099570A - Composition for prevention and treatment of dermatitis disease containing complex herbal extract as an active ingredient - Google Patents
Composition for prevention and treatment of dermatitis disease containing complex herbal extract as an active ingredient Download PDFInfo
- Publication number
- KR20080099570A KR20080099570A KR1020070045284A KR20070045284A KR20080099570A KR 20080099570 A KR20080099570 A KR 20080099570A KR 1020070045284 A KR1020070045284 A KR 1020070045284A KR 20070045284 A KR20070045284 A KR 20070045284A KR 20080099570 A KR20080099570 A KR 20080099570A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- dermatitis
- composition
- acid
- lotion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 239000012676 herbal extract Substances 0.000 title claims abstract description 42
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 22
- 238000011282 treatment Methods 0.000 title claims abstract description 17
- 230000002265 prevention Effects 0.000 title claims abstract description 12
- 239000004480 active ingredient Substances 0.000 title abstract description 14
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 30
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 30
- 239000002537 cosmetic Substances 0.000 claims abstract description 24
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229910052737 gold Inorganic materials 0.000 claims abstract description 19
- 239000010931 gold Substances 0.000 claims abstract description 19
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 18
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 18
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 18
- 229940010454 licorice Drugs 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 229910052709 silver Inorganic materials 0.000 claims abstract description 9
- 239000004332 silver Substances 0.000 claims abstract description 9
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 7
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 7
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 7
- 240000002045 Guettarda speciosa Species 0.000 claims abstract description 6
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 6
- 241001226779 Royena whyteana Species 0.000 claims abstract description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000018723 Terminalia ivorensis Nutrition 0.000 claims abstract description 4
- 239000011593 sulfur Substances 0.000 claims abstract description 4
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 4
- -1 patch Substances 0.000 claims description 66
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 26
- 239000006210 lotion Substances 0.000 claims description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000009472 formulation Methods 0.000 claims description 17
- 239000006071 cream Substances 0.000 claims description 15
- 235000011187 glycerol Nutrition 0.000 claims description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 235000016709 nutrition Nutrition 0.000 claims description 8
- 230000035764 nutrition Effects 0.000 claims description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 7
- 239000008213 purified water Substances 0.000 claims description 7
- 244000246386 Mentha pulegium Species 0.000 claims description 6
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 6
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 6
- 208000003251 Pruritus Diseases 0.000 claims description 6
- 241000411851 herbal medicine Species 0.000 claims description 6
- 235000001050 hortel pimenta Nutrition 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 230000003020 moisturizing effect Effects 0.000 claims description 5
- 239000000344 soap Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 206010012442 Dermatitis contact Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 208000010247 contact dermatitis Diseases 0.000 claims description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 235000015927 pasta Nutrition 0.000 claims description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 3
- 102100036441 Amyloid-beta A4 precursor protein-binding family A member 2 Human genes 0.000 claims description 2
- 101710093616 Amyloid-beta A4 precursor protein-binding family A member 2 Proteins 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000008269 hand cream Substances 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims 3
- 210000003491 skin Anatomy 0.000 abstract description 42
- 230000000694 effects Effects 0.000 abstract description 13
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract description 12
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 108020004999 messenger RNA Proteins 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 210000004927 skin cell Anatomy 0.000 abstract description 6
- 230000002269 spontaneous effect Effects 0.000 abstract description 4
- 230000000903 blocking effect Effects 0.000 abstract description 3
- 230000006698 induction Effects 0.000 abstract description 3
- 102100023698 C-C motif chemokine 17 Human genes 0.000 abstract description 2
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 abstract description 2
- 239000002253 acid Substances 0.000 description 23
- 235000014113 dietary fatty acids Nutrition 0.000 description 18
- 239000000194 fatty acid Substances 0.000 description 18
- 229930195729 fatty acid Natural products 0.000 description 18
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 16
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 14
- 239000003925 fat Substances 0.000 description 13
- 235000019197 fats Nutrition 0.000 description 13
- 102000003826 Chemokine CCL17 Human genes 0.000 description 12
- 108010082169 Chemokine CCL17 Proteins 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 229940088594 vitamin Drugs 0.000 description 9
- 229930003231 vitamin Natural products 0.000 description 9
- 235000013343 vitamin Nutrition 0.000 description 9
- 239000011782 vitamin Substances 0.000 description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 7
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 7
- 229920001577 copolymer Polymers 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 210000004969 inflammatory cell Anatomy 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 241001474374 Blennius Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 210000004207 dermis Anatomy 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 241000736199 Paeonia Species 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000686 essence Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- HJRJRUMKQCMYDL-UHFFFAOYSA-N 1-chloro-2,4,6-trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(Cl)C([N+]([O-])=O)=C1 HJRJRUMKQCMYDL-UHFFFAOYSA-N 0.000 description 4
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 4
- 241000382455 Angelica sinensis Species 0.000 description 4
- 206010003645 Atopy Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- 239000009122 Saeng-Ji-Hwang Substances 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 4
- 230000037336 dry skin Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000001023 inorganic pigment Substances 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- CRSOQBOWXPBRES-UHFFFAOYSA-N neopentane Chemical compound CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 description 4
- 229940049964 oleate Drugs 0.000 description 4
- 239000012860 organic pigment Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristoyl-sn-glycerol Natural products CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- 239000004909 Moisturizer Substances 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 235000006484 Paeonia officinalis Nutrition 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000002280 amphoteric surfactant Substances 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229920000223 polyglycerol Polymers 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 150000003408 sphingolipids Chemical class 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- 235000014692 zinc oxide Nutrition 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- DHGBAFGZLVRESL-UHFFFAOYSA-N 14-methylpentadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C DHGBAFGZLVRESL-UHFFFAOYSA-N 0.000 description 2
- UWNADWZGEHDQAB-UHFFFAOYSA-N 2,5-dimethylhexane Chemical group CC(C)CCC(C)C UWNADWZGEHDQAB-UHFFFAOYSA-N 0.000 description 2
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- 235000018865 Angelica gigas Nutrition 0.000 description 2
- 240000001810 Angelica gigas Species 0.000 description 2
- ZCTQGTTXIYCGGC-UHFFFAOYSA-N Benzyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 ZCTQGTTXIYCGGC-UHFFFAOYSA-N 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 102000004498 CCR4 Receptors Human genes 0.000 description 2
- 108010017317 CCR4 Receptors Proteins 0.000 description 2
- 240000004160 Capsicum annuum Species 0.000 description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- SLKPBCXNFNIJSV-HNNXBMFYSA-N Cuparene Chemical compound C1=CC(C)=CC=C1[C@@]1(C)C(C)(C)CCC1 SLKPBCXNFNIJSV-HNNXBMFYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- QSIXTSXIETZHGN-UHFFFAOYSA-N Uralene Chemical compound O1C2=CC=C(O)C(O)=C2C(=O)C(OC)=C1C1=CC(O)=C(O)C=C1CC=C(C)C QSIXTSXIETZHGN-UHFFFAOYSA-N 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 229960000956 coumarin Drugs 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 2
- MVLVMROFTAUDAG-UHFFFAOYSA-N ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC MVLVMROFTAUDAG-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 239000010445 mica Substances 0.000 description 2
- 229910052618 mica group Inorganic materials 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- GYHFUZHODSMOHU-UHFFFAOYSA-N nonanal Chemical compound CCCCCCCCC=O GYHFUZHODSMOHU-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 235000019488 nut oil Nutrition 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 2
- SFBIZPBTKROSDE-UHFFFAOYSA-N octyl 2-hydroxypropanoate Chemical compound CCCCCCCCOC(=O)C(C)O SFBIZPBTKROSDE-UHFFFAOYSA-N 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- AFDXODALSZRGIH-UHFFFAOYSA-N p-coumaric acid methyl ether Natural products COC1=CC=C(C=CC(O)=O)C=C1 AFDXODALSZRGIH-UHFFFAOYSA-N 0.000 description 2
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 2
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 2
- PHVSWPDOXIQPTN-UHFFFAOYSA-N sedanonic acid Chemical compound CCCCC(=O)C1CCCC=C1C(O)=O PHVSWPDOXIQPTN-UHFFFAOYSA-N 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 description 1
- DEQUKPCANKRTPZ-UHFFFAOYSA-N (2,3-dihydroxyphenyl)-phenylmethanone Chemical compound OC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1O DEQUKPCANKRTPZ-UHFFFAOYSA-N 0.000 description 1
- BOCBOJPUWMTAJB-UHFFFAOYSA-N (2-butylphenyl) 2-hydroxybenzoate Chemical compound CCCCC1=CC=CC=C1OC(=O)C1=CC=CC=C1O BOCBOJPUWMTAJB-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- NLSMPWTZYGSAEU-CYUNEVMDSA-N (2s,3r,4s,5s,6r)-2-[7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromenylium-5-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;chloride Chemical compound [Cl-].C1=C(O)C(OC)=CC(C=2C(=CC=3C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 NLSMPWTZYGSAEU-CYUNEVMDSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- OUZOBPPZPCBJAR-UHFFFAOYSA-N 14-methylpentadecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C OUZOBPPZPCBJAR-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- WPIOBXGJZUSKGK-UHFFFAOYSA-N 16-methylheptadecyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C WPIOBXGJZUSKGK-UHFFFAOYSA-N 0.000 description 1
- MVUWRLHKGKEGSS-UHFFFAOYSA-N 16-methylheptadecyl octanoate Chemical compound CCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C MVUWRLHKGKEGSS-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- QZJDYFVPLXBWTK-UHFFFAOYSA-N 2-(diethylamino)ethyl octadecanoate Chemical class CCCCCCCCCCCCCCCCCC(=O)OCCN(CC)CC QZJDYFVPLXBWTK-UHFFFAOYSA-N 0.000 description 1
- ZMXUPLNMYABPEB-UHFFFAOYSA-N 2-[[2-(dodecanoylamino)acetyl]amino]acetic acid Chemical compound CCCCCCCCCCCC(=O)NCC(=O)NCC(O)=O ZMXUPLNMYABPEB-UHFFFAOYSA-N 0.000 description 1
- QUBNFZFTFXTLKH-UHFFFAOYSA-N 2-aminododecanoic acid Chemical compound CCCCCCCCCCC(N)C(O)=O QUBNFZFTFXTLKH-UHFFFAOYSA-N 0.000 description 1
- AKVBCGQVQXPRLD-UHFFFAOYSA-N 2-aminooctanoic acid Chemical compound CCCCCCC(N)C(O)=O AKVBCGQVQXPRLD-UHFFFAOYSA-N 0.000 description 1
- KNEFRHCUYCDKRK-UHFFFAOYSA-N 2-benzyl-3-phenylprop-2-enoic acid Chemical compound C=1C=CC=CC=1C=C(C(=O)O)CC1=CC=CC=C1 KNEFRHCUYCDKRK-UHFFFAOYSA-N 0.000 description 1
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 1
- GLCFQKXOQDQJFZ-UHFFFAOYSA-N 2-ethylhexyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(CC)CCCC GLCFQKXOQDQJFZ-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 1
- KXGFMDJXCMQABM-UHFFFAOYSA-N 2-methoxy-6-methylphenol Chemical compound [CH]OC1=CC=CC([CH])=C1O KXGFMDJXCMQABM-UHFFFAOYSA-N 0.000 description 1
- LEEDMQGKBNGPDN-UHFFFAOYSA-N 2-methylnonadecane Chemical compound CCCCCCCCCCCCCCCCCC(C)C LEEDMQGKBNGPDN-UHFFFAOYSA-N 0.000 description 1
- HTNFLUQQANUSLR-UHFFFAOYSA-N 2-octanoyloxyethyl octanoate Chemical compound CCCCCCCC(=O)OCCOC(=O)CCCCCCC HTNFLUQQANUSLR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- QULIOZDJZXKLNY-UHFFFAOYSA-N 3,4,5-trihydroxy-2-propylbenzoic acid Chemical compound CCCC1=C(O)C(O)=C(O)C=C1C(O)=O QULIOZDJZXKLNY-UHFFFAOYSA-N 0.000 description 1
- ZYIFAFPFZXUPAX-UHFFFAOYSA-N 3-(dimethylamino)propyl octadecanoate Chemical class CCCCCCCCCCCCCCCCCC(=O)OCCCN(C)C ZYIFAFPFZXUPAX-UHFFFAOYSA-N 0.000 description 1
- SDZHIRPZKXFSBX-UHFFFAOYSA-N 3-(dodecanoylamino)propanoic acid;zinc Chemical compound [Zn].CCCCCCCCCCCC(=O)NCCC(O)=O SDZHIRPZKXFSBX-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- IRLNKOAURQPXIQ-WWWUCTDISA-N Apiopaeonoside Natural products O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@](O)(CO)CO3)O2)cc(OC)cc1 IRLNKOAURQPXIQ-WWWUCTDISA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 241000751139 Beauveria bassiana Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 101710112528 C-C motif chemokine 17 Proteins 0.000 description 1
- FTFSBTUNGWWUHI-UHFFFAOYSA-N CC(C(C(CO)(CO)CO)CC)(C)C Chemical compound CC(C(C(CO)(CO)CO)CC)(C)C FTFSBTUNGWWUHI-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000272194 Ciconiiformes Species 0.000 description 1
- UXDIXFDKSPCUIX-AXFHLTTASA-N Cnidilide Chemical compound C1=CCC[C@@H]2[C@H](CCCC)OC(=O)[C@@H]21 UXDIXFDKSPCUIX-AXFHLTTASA-N 0.000 description 1
- 241000212948 Cnidium Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- AVGPOAXYRRIZMM-BYPYZUCNSA-N D-apiose Chemical compound OCC(O)(CO)[C@@H](O)C=O AVGPOAXYRRIZMM-BYPYZUCNSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- YJHVMPKSUPGGPZ-UHFFFAOYSA-N Dihydro-beta-eudesmol Natural products C1CC(C(C)(C)O)CC2C(C)CCCC21C YJHVMPKSUPGGPZ-UHFFFAOYSA-N 0.000 description 1
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000416536 Euproctis pseudoconspersa Species 0.000 description 1
- PYVHTIWHNXTVPF-UHFFFAOYSA-N F.F.F.F.C=C Chemical compound F.F.F.F.C=C PYVHTIWHNXTVPF-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- 241001198924 Forsythia koreana Species 0.000 description 1
- 235000011447 Geum Nutrition 0.000 description 1
- 241000220313 Geum Species 0.000 description 1
- 235000004036 Glehnia littoralis Nutrition 0.000 description 1
- 244000146486 Glehnia littoralis Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- OXPCWUWUWIWSGI-MSUUIHNZSA-N Lauryl oleate Chemical compound CCCCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC OXPCWUWUWIWSGI-MSUUIHNZSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000004640 Melamine resin Substances 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 235000018978 Mentha arvensis Nutrition 0.000 description 1
- 240000007707 Mentha arvensis Species 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- UPJFTVFLSIQQAV-KOLCDFICSA-N Neocnidilide Chemical compound C1CC[C@H]2[C@H](CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-KOLCDFICSA-N 0.000 description 1
- UPJFTVFLSIQQAV-UHFFFAOYSA-N Neocnidilide Natural products C1CCC2C(CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- HXCGUCZXPFBNRD-DNLMCPORSA-N Nodakenin Chemical compound CC(C)([C@@H]1OC2=CC=3OC(=O)C=CC=3C=C2C1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HXCGUCZXPFBNRD-DNLMCPORSA-N 0.000 description 1
- HXCGUCZXPFBNRD-QVYYAULWSA-N Nodakenin Natural products O(C(C)(C)[C@@H]1Oc2c(cc3c(OC(=O)C=C3)c2)C1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HXCGUCZXPFBNRD-QVYYAULWSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- FRTAUWORWHSFAY-UHFFFAOYSA-N Onoside Natural products COc1cc(cc2OCOc12)C3CC(=O)c4cc(OC5OC(CO)C(O)C(O)C5O)ccc4O3 FRTAUWORWHSFAY-UHFFFAOYSA-N 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- IDZZECHGWAZTIB-NYBIBFQCSA-N Paeonolide Chemical compound COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@@H](O)CO3)O)O2)O)=C1 IDZZECHGWAZTIB-NYBIBFQCSA-N 0.000 description 1
- IDZZECHGWAZTIB-WPQJODJHSA-N Paeonolide Natural products O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]3[C@@H](O)[C@H](O)[C@@H](O)CO3)O2)cc(OC)cc1 IDZZECHGWAZTIB-WPQJODJHSA-N 0.000 description 1
- AVIUTYMRHHBXPB-UXXRCYHCSA-N Paeonoside Natural products COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 AVIUTYMRHHBXPB-UXXRCYHCSA-N 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- NKSOSPOXQKNIKJ-CLFAGFIQSA-N Polyoxyethylene dioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOC(=O)CCCCCCC\C=C/CCCCCCCC NKSOSPOXQKNIKJ-CLFAGFIQSA-N 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- DUFKCOQISQKSAV-UHFFFAOYSA-N Polypropylene glycol (m w 1,200-3,000) Chemical compound CC(O)COC(C)CO DUFKCOQISQKSAV-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000951376 Schizonepeta tenuifolia Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 240000000067 Spirodela polyrhiza Species 0.000 description 1
- 235000014249 Spirodela polyrhiza Nutrition 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 1
- LNOHXHDWGCMVCO-UHFFFAOYSA-N Wogonoside Natural products C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1OC1OC(C(O)=O)C(O)C(O)C1O LNOHXHDWGCMVCO-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- TUYRNAGGIJZRNM-LBHUVFDKSA-N [(2s)-2-[(2r)-4-hexadecanoyloxy-3-hydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(OC(=O)CCCCCCCCCCCCCCC)=C1O TUYRNAGGIJZRNM-LBHUVFDKSA-N 0.000 description 1
- PRLUQOOFPFWUKQ-KKTNLPSRSA-N [(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl] (z)-octadec-9-enoate Chemical compound C1C[C@@H]2[C@@]3(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@]21C PRLUQOOFPFWUKQ-KKTNLPSRSA-N 0.000 description 1
- XKMYWNHZAQUEPY-YZGJEOKZSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 12-hydroxyoctadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCC(O)CCCCCC)C1 XKMYWNHZAQUEPY-YZGJEOKZSA-N 0.000 description 1
- JBBRZDLNVILTDL-XNTGVSEISA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 16-methylheptadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCC(C)C)C1 JBBRZDLNVILTDL-XNTGVSEISA-N 0.000 description 1
- WUBKCBOQNXUQDU-UHFFFAOYSA-N [2-(dihydroxymethoxy)phenyl]-phenylmethanone Chemical compound OC(O)OC1=CC=CC=C1C(=O)C1=CC=CC=C1 WUBKCBOQNXUQDU-UHFFFAOYSA-N 0.000 description 1
- YRXGUZPUZBCGST-UHFFFAOYSA-N [2-(hydroxymethoxy)phenyl]-phenylmethanone Chemical compound OCOC1=CC=CC=C1C(=O)C1=CC=CC=C1 YRXGUZPUZBCGST-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- IDZZECHGWAZTIB-UHFFFAOYSA-N affinoside Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)=C1 IDZZECHGWAZTIB-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000013572 airborne allergen Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- IPZIYGAXCZTOMH-UHFFFAOYSA-N alpha-eudesmol Natural products CC1=CCCC2CCC(CC12)C(C)(C)O IPZIYGAXCZTOMH-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- YSJGOMATDFSEED-UHFFFAOYSA-M behentrimonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)C YSJGOMATDFSEED-UHFFFAOYSA-M 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical class CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- VZWMKHUMEIECPK-UHFFFAOYSA-M benzyl-dimethyl-octadecylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 VZWMKHUMEIECPK-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- XFSVWZZZIUIYHP-UHFFFAOYSA-N beta-Eudesmol Natural products CC(C)(O)C1CCC2CCCC(=C)C2C1 XFSVWZZZIUIYHP-UHFFFAOYSA-N 0.000 description 1
- BOPIMTNSYWYZOC-VNHYZAJKSA-N beta-eudesmol Chemical compound C1CCC(=C)[C@@H]2C[C@H](C(C)(O)C)CC[C@]21C BOPIMTNSYWYZOC-VNHYZAJKSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- WMNULTDOANGXRT-UHFFFAOYSA-N bis(2-ethylhexyl) butanedioate Chemical compound CCCCC(CC)COC(=O)CCC(=O)OCC(CC)CCCC WMNULTDOANGXRT-UHFFFAOYSA-N 0.000 description 1
- 229940073609 bismuth oxychloride Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ULBTUVJTXULMLP-UHFFFAOYSA-N butyl octadecanoate Chemical group CCCCCCCCCCCCCCCCCC(=O)OCCCC ULBTUVJTXULMLP-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229950005197 butylphthalide Drugs 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229940105847 calamine Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- AGNCRIYGRWNVIF-UHFFFAOYSA-N calcium;2-(dodecanoylamino)acetic acid Chemical compound [Ca].CCCCCCCCCCCC(=O)NCC(O)=O AGNCRIYGRWNVIF-UHFFFAOYSA-N 0.000 description 1
- CEGYXKLZALIAEI-UHFFFAOYSA-N calcium;2-(dodecanoylamino)ethanesulfonic acid Chemical compound [Ca].CCCCCCCCCCCC(=O)NCCS(O)(=O)=O CEGYXKLZALIAEI-UHFFFAOYSA-N 0.000 description 1
- YEFORLIOCBRMFS-UHFFFAOYSA-N calcium;2-(hexadecanoylamino)ethanesulfonic acid Chemical compound [Ca].CCCCCCCCCCCCCCCC(=O)NCCS(O)(=O)=O YEFORLIOCBRMFS-UHFFFAOYSA-N 0.000 description 1
- HOQGRRFKKLWWOO-UHFFFAOYSA-N calcium;3-(dodecanoylamino)propanoic acid Chemical compound [Ca].CCCCCCCCCCCC(=O)NCCC(O)=O HOQGRRFKKLWWOO-UHFFFAOYSA-N 0.000 description 1
- HIAAVKYLDRCDFQ-UHFFFAOYSA-L calcium;dodecanoate Chemical compound [Ca+2].CCCCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O HIAAVKYLDRCDFQ-UHFFFAOYSA-L 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 description 1
- 229940072104 cholesteryl hydroxystearate Drugs 0.000 description 1
- 229940073724 cholesteryl isostearate Drugs 0.000 description 1
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- VQWFNAGFNGABOH-UHFFFAOYSA-K chromium(iii) hydroxide Chemical compound [OH-].[OH-].[OH-].[Cr+3] VQWFNAGFNGABOH-UHFFFAOYSA-K 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- UXDIXFDKSPCUIX-UHFFFAOYSA-N condilide Natural products C1=CCCC2C(CCCC)OC(=O)C21 UXDIXFDKSPCUIX-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- SLKPBCXNFNIJSV-UHFFFAOYSA-N cuparene Natural products C1=CC(C)=CC=C1C1(C)C(C)(C)CCC1 SLKPBCXNFNIJSV-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- OFADGACXTNUQLM-UHFFFAOYSA-N decanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O OFADGACXTNUQLM-UHFFFAOYSA-N 0.000 description 1
- PHMQYKDOTWAOBI-UHFFFAOYSA-N decanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCC(O)=O PHMQYKDOTWAOBI-UHFFFAOYSA-N 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- MIMDHDXOBDPUQW-UHFFFAOYSA-N dioctyl decanedioate Chemical compound CCCCCCCCOC(=O)CCCCCCCCC(=O)OCCCCCCCC MIMDHDXOBDPUQW-UHFFFAOYSA-N 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- WVRVMHCZDFFAFB-UHFFFAOYSA-N epsilon-Cuprenene Natural products C1=CC(C)=CCC1C1(C)C(C)(C)CCC1 WVRVMHCZDFFAFB-UHFFFAOYSA-N 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- HPMLGOFBKNGJAM-ONEGZZNKSA-N ethyl (e)-3-(1h-imidazol-5-yl)prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CN=CN1 HPMLGOFBKNGJAM-ONEGZZNKSA-N 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- AVIUTYMRHHBXPB-UHFFFAOYSA-N glucopaeonol Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(CO)O2)O)=C1 AVIUTYMRHHBXPB-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- PQTCMBYFWMFIGM-UHFFFAOYSA-N gold silver Chemical compound [Ag].[Au] PQTCMBYFWMFIGM-UHFFFAOYSA-N 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052864 hemimorphite Inorganic materials 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- FPMPNVIMFPEKRN-UHFFFAOYSA-N hexyl 16-methylheptadecanoate Chemical compound CCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C FPMPNVIMFPEKRN-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 102000044064 human CCL17 Human genes 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- OLOOJGVNMBJLLR-UHFFFAOYSA-N imperatorin Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OCC=C(C)C OLOOJGVNMBJLLR-UHFFFAOYSA-N 0.000 description 1
- XKVWLLRDBHAWBL-UHFFFAOYSA-N imperatorin Natural products CC(=CCOc1c2OCCc2cc3C=CC(=O)Oc13)C XKVWLLRDBHAWBL-UHFFFAOYSA-N 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- XFFQVRFGLSBFON-DEFKTLOSSA-N kaempferol 3,7-di-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C(C=3C=CC(O)=CC=3)OC2=C1 XFFQVRFGLSBFON-DEFKTLOSSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- LAQFLZHBVPULPL-UHFFFAOYSA-N methyl(phenyl)silicon Chemical compound C[Si]C1=CC=CC=C1 LAQFLZHBVPULPL-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000008820 moutan cortex Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- HXCGUCZXPFBNRD-UHFFFAOYSA-N nodakenine Natural products C1C2=CC=3C=CC(=O)OC=3C=C2OC1C(C)(C)OC1OC(CO)C(O)C(O)C1O HXCGUCZXPFBNRD-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- PIUVNPNBPWVVKZ-UHFFFAOYSA-N octadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC PIUVNPNBPWVVKZ-UHFFFAOYSA-N 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 229960003921 octisalate Drugs 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IIGMITQLXAGZTL-UHFFFAOYSA-N octyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC IIGMITQLXAGZTL-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229930194807 paeonin Natural products 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 239000010702 perfluoropolyether Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- LYKRPDCJKSXAHS-UHFFFAOYSA-N phenyl-(2,3,4,5-tetrahydroxyphenyl)methanone Chemical compound OC1=C(O)C(O)=CC(C(=O)C=2C=CC=CC=2)=C1O LYKRPDCJKSXAHS-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 description 1
- 235000007221 pinoresinol Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920005668 polycarbonate resin Polymers 0.000 description 1
- 239000004431 polycarbonate resin Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical group CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000010499 rapseed oil Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical class [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- YFGAFXCSLUUJRG-WCCKRBBISA-M sodium;(2s)-2-amino-5-(diaminomethylideneamino)pentanoate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCCN=C(N)N YFGAFXCSLUUJRG-WCCKRBBISA-M 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- CPJKKWDCUOOTEW-UHFFFAOYSA-N sylvatesmin Natural products C1=C(OC)C(OC)=CC=C1C1C(COC2C=3C=C(OC)C(O)=CC=3)C2CO1 CPJKKWDCUOOTEW-UHFFFAOYSA-N 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- APVVRLGIFCYZHJ-UHFFFAOYSA-N trioctyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCC)CC(=O)OCCCCCCCC APVVRLGIFCYZHJ-UHFFFAOYSA-N 0.000 description 1
- COXJMKGEQAWXNP-UHFFFAOYSA-N tris(14-methylpentadecyl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(C)CCCCCCCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCCCCCCCC(C)C)CC(=O)OCCCCCCCCCCCCCC(C)C COXJMKGEQAWXNP-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 235000013799 ultramarine blue Nutrition 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
- LNOHXHDWGCMVCO-NTKSAMNMSA-N wogonin 7-O-beta-D-glucuronide Chemical compound C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LNOHXHDWGCMVCO-NTKSAMNMSA-N 0.000 description 1
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 당귀, 목단피, 생지황, 감초, 금은화, 방풍, 부평초, 연교, 적작약, 천궁, 형개, 백강잠, 박하, 서우각 및 황금의 복합 생약 추출물을 유효성분으로 함유하는 피부염 질환의 예방 및 치료용 조성물에 관한 것으로, 상세하게는 본 발명의 복합 생약 추출물은 자발적 아토피성 피부염 유발 모델인 NC/Nga 마우스에 적용 시, 아토피 피부염 억제 및 피부 세포주에서의 TARC mRNA 생성을 차단하는 효과를 확인함으로써, 피부염 질환의 예방 및 치료용 피부 외용 약학조성물 및 화장료 조성물로 유용하게 이용될 수 있다. The present invention is for the prevention and treatment of dermatitis diseases containing the complex herbal extracts of Angelica, black bark, raw sulfur, licorice, gold and silver, windproof, Bupyeongcho, Yeongyo, Red Peony, Cheongung, Hyungae, Baekjap, Mint, Seowookak and Gold as active ingredients. In particular, the complex herbal extract of the present invention, when applied to NC / Nga mouse of spontaneous atopic dermatitis induction model, by confirming the effect of inhibiting atopic dermatitis and blocking TARC mRNA production in skin cell lines, dermatitis It can be usefully used as an external skin pharmaceutical composition and cosmetic composition for the prevention and treatment of diseases.
Description
도 1은 아토피 피부염 유발 모델인 NC/Nga 마우스를 이용한 실험 일정을 나타낸 도이고, Figure 1 is a diagram showing the schedule of experiments using NC / Nga mouse, atopic dermatitis induced model,
도 2는 복합 생약 추출물 (SP-1)을 도포한 마우스의 등 표면을 나타낸 도이며, Figure 2 is a view showing the back surface of the mouse coated with the composite herbal extract (SP-1),
도 3은 복합 생약 추출물 (SP-1)을 도포한 피부조직표본을 나타낸 도이고, Figure 3 is a diagram showing a sample of skin tissue coated with a composite herbal extract (SP-1),
도 4는 복합 생약 추출물 (SP-1) 투여에 따른 가피형성피부의 비율을 나타낸 도이며, Figure 4 is a diagram showing the proportion of the skin forming skin according to the administration of the complex herbal extract (SP-1),
도 5는 복합 생약 추출물 (SP-1) 투여에 따른 진피로의 염증세포 침윤 정도를 나타낸 도이고, 5 is a diagram showing the degree of inflammatory cell infiltration into the dermis following administration of the complex herbal extract (SP-1),
도 6은 복합 생약 추출물 (SP-1) 투여에 따른 표피 두께를 나타낸 도이며, Figure 6 is a diagram showing the epidermal thickness according to the administration of complex herbal extract (SP-1),
도 7은 복합 생약 추출물 (SP-1)이 피부세포주에서 TARC mRNA 생성에 미치는 효과를 RT-PCR로 분석한 도이다. Figure 7 is an analysis of the effect of the compound herbal extract (SP-1) on TARC mRNA production in skin cell lines by RT-PCR.
본 발명은 당귀, 목단피, 생지황, 감초, 금은화, 방풍, 부평초, 연교, 적작약, 천궁, 형개, 백강잠, 박하, 서우각 및 황금의 복합 생약 추출물을 유효성분으로 함유하는 피부염 질환의 예방 및 치료용 조성물에 관한 것이다. The present invention is for the prevention and treatment of dermatitis diseases containing the complex herbal extracts of Angelica, black bark, raw sulfur, licorice, gold and silver, windproof, Bupyeongcho, Yeongyo, Red Peony, Cheongung, Hyungae, Baekjap, Mint, Seowookak and Gold as active ingredients. It relates to a composition.
인체의 피부는 물리적, 화학적으로 외계로부터 신체를 보호하는 동시에 전신의 대사에 필요한 생화학적 기능을 영위하는 생명유지에 필수 불가결한 기관이다. 사람의 피부 (머리털, 손, 발톱 등을 포함)에 나타나는 모든 이상 소견을 피부질환, 즉 피부병이라 한다. 피부는 신체의 표면을 덮고 있으므로 외계로부터 자극이나 여러 병원체에 직접 접촉될 기회가 많고, 체내로부터 영향을 강하게 받는다. 더욱이 피부의 근소한 변화도 눈으로 보고 손으로 만질 수 있으며, 병변부의 일부를 채취하여 병리조직학적으로 검사하거나, 미생물의 검색 등의 검사를 하기 쉽고, 개개의 질병의 진단을 명확하게 하는 것이 용이하므로, 그 종류는 다른 장기에 비하여 상당한 수에 이르며, 병명도 복잡 다양하다. The skin of the human body is an indispensable organ for the maintenance of life, which physically and chemically protects the body from extraterrestrial and performs the biochemical functions necessary for metabolism of the whole body. All abnormalities that appear on human skin (including hair, hands, and toenails) are called skin diseases, or skin diseases. Since the skin covers the surface of the body, there are many opportunities for direct contact with stimuli or various pathogens from the outside, and are strongly influenced by the body. Furthermore, even minor changes in the skin can be seen by eye and touched by hand, and it is easy to examine pathological histologically by extracting a part of the lesion, to examine microorganisms, and to clearly diagnose the diagnosis of individual diseases. In contrast, their types are considerably more numerous than other organs, and their names vary in complexity.
비교적 흔한 피부질환으로는 아토피 피부염, 접촉성 피부염, 지루성 피부염, 두드러기, 무좀, 완선, 건선, 단순포진/대상포진, 피부 건조증, 주부습진, 여드름 등이 있다. 이 중 아토피성 피부염은 심한 소양감(搔痒感)을 가지는 재발성의 만성 피부염으로 그 원인이 현재까지 명확하게 규명되지 않았으나, 세계 전 인구의 10 내지 20%가 이 피부염으로 고통받는 것으로 추정되고 있다. Relatively common skin diseases include atopic dermatitis, contact dermatitis, seborrheic dermatitis, urticaria, athlete's foot, psoriasis, psoriasis, herpes simplex / shingles, dry skin, housewives and acne. Among them, atopic dermatitis is a recurrent chronic dermatitis with severe pruritus. The cause of the disease is not clearly identified so far, but it is estimated that 10 to 20% of the world's population suffers from this dermatitis.
또한, 환경 오염 등에 의한 공기 매개성 알러지 (allergy) 원인 물질 (allergen)의 증가와 건조성 피부를 형성시키는 조건의 증가 등으로 인하여 최근 수십 년 동안 아토피성 피부염에 대한 유병율이 계속 상승하고 있다. In addition, the prevalence of atopic dermatitis continues to increase in recent decades due to the increase in allergens causing airborne allergens due to environmental pollution and the increase in conditions for forming dry skin.
아토피 (Atopy)란 “부적당한(out of place)” 또는 그리이스어로 “특이한(strange)”이란 의미를 내포하고 있다. 아토피 피부염은 홍반(erythema), 부종, 심한 소양증과 건조증, 침출과 부스럼 닦지를 특징으로 하고 급성기에는 표피내에 수포를 형성하며 만성기에는 피부의 비후가 생기는 피부염증징환의 일종으로, 아토피성 체질을 주로 하여 발생하는 특유의 임상특징과 만성적인 특징을 지니는 피부염으로 알러지성 습진, 소아태열, 범발성 신경피부염 등으로 불리기도 한다. Atopy has the meaning of “out of place” or in Greek “strange”. Atopic dermatitis is characterized by erythema, swelling, severe pruritus and dryness, leaching and swelling, and in the acute phase forms blisters in the epidermis and chronic thickening of the skin that causes skin thickening. Dermatitis with specific clinical and chronic characteristics that occur is sometimes referred to as allergic eczema, pediatric fever, and neurodegenerative dermatitis.
우리나라 0-4세 유아 100명당 18명이 아토피를 앓고 있으며, 전체 아토피 환자 중에서 0-9세 환자의 비율을 보면 63.6%에 달하고 있다. 이는 아토피와 같은 만성 염증성 질환이 소아들에 심각하게 발생하고 있음을 시사한다 (국민건강보험공단 심사평가원, 통계청; 2000-2003년 자료). 최근 수십 년간 선진국에서는 아토피질환의 이환율이 상당히 증가하는 추세에 있으며, 우리나라에서도 최근 알레르기 질환의 급증과 함께 아토피 피부염 환자가 증가하고 있다. 대한 소아알레르기 및 호흡기학회에서 2000년도에 전국의 초등학생과 중학생 43,045명을 대상으로 설문조사한 결과에 따르면, 초등학생의 24.9%, 중학생의 12.8%가 아토피피부염을 진단 받은 것으로 나타날 정도로 그 국민 건강에 미치는 위해성은 심각하다고 할 수 있다. 아토피성 피부염 환자는 2003년에 전국적으로 115만명이 발병하였고, 이는 전국민 중 2.4%에 해당하는 수치이며, 아토피 치료를 위해서 들어간 돈이 의료보험 산출액 만으로도 292억원에 이를 정도로 사회적 비용도 큰 질환이다. 더불어 한방치료비용과 민간요법등의 비용 등을 합산시에는 그 사회적 비용이 600억원을 상회할 것으로 예상되는 등 국민경제에 미치는 심각성도 큰 실정이다. A total of 18 children in 100 Korean infants aged 0-4 years have atopic dermatitis, and 63.6% of all atopy patients are 0-9 years old. This suggests that chronic inflammatory diseases, such as atopy, are seriously occurring in children (National Institutes of Health Insurance Review and Evaluation, National Statistical Office; 2000-2003 data). In the recent decades, the prevalence of atopic diseases has increased considerably in developed countries, and in Korea, the number of atopic dermatitis patients has increased with the recent surge of allergic diseases. According to a survey of 43,045 elementary and junior high school students nationwide in 2000 by the Korean Academy of Pediatric Allergy and Respiratory Diseases, 24.9% of elementary school students and 12.8% of middle school students were diagnosed with atopic dermatitis. Is serious. The number of atopic dermatitis cases was 1.15 million nationwide in 2003, which is 2.4% of the nation's citizens, and the social cost is so high that medical expenses can reach 22.9 billion won. . In addition, the social cost is expected to exceed 60 billion won when the costs of oriental medical treatment and private therapy are combined.
양방에서의 아토피성 피부염 또는 비염의 약물치료로는 스테로이드, 항히스타민제, 항생제등을 사용한다. 그러나 이들 제제의 경우 일시적 치료효능은 보이나 곧 재발한다는 단점을 갖고 있으며, 부신피질호르몬인 스테로이드제의 경우 강력한 소염작용과 면역억제작용으로 효과가 우수하지만 그 부작용이 심각하다. 이런 이유로 소아성 만성 염증질환에 대한 한방치료요법의 유용성은 큰 관심을 얻고 있다. 한방치료의 장점으로는 1)인체투여시의 약효평가가 임상적으로 이미 확립되어 있으며, 2) 복방을 활용한 독성감소 및 효능극대화의 방법과 이론적 개념이 임상적으로 축적되어 있으며, 3) 양방의 치료가 어렵다고 알려진 만성 및 난치성 질환에 유효한 효능을 갖는 다는 사실을 들 수가 있다. 따라서 한방을 이용하여 소아성 아토피성 피부염을 치료하려는 시도가 빈번하며 치료효과 또한 몇몇 한약재의 경우, 임상적으로는 우수한 것으로 알려져 있다. Drug treatment of atopic dermatitis or rhinitis in both cases uses steroids, antihistamines, antibiotics, and the like. However, in the case of these preparations, the temporary therapeutic effect is seen, but has the disadvantage of recurring soon, and the corticosteroid, which is an corticosteroid, has excellent effects due to its strong anti-inflammatory and immunosuppressive effects, but its side effects are serious. For this reason, the utility of herbal remedies for pediatric chronic inflammatory diseases has attracted great attention. Advantages of herbal treatment include: 1) Clinical evaluation of human efficacy has already been established, and 2) methods and theoretical concepts for reducing toxicity and maximizing efficacy using the abdomen are accumulated clinically. It can be said that it has an effective effect on chronic and refractory diseases known to be difficult to treat. Therefore, attempts to treat pediatric atopic dermatitis using herbal medicines are frequent, and some of the herbal medicines are known to be clinically excellent.
참당귀(Angelica gigas Nakai)는 산야, 계곡의 습지에 나며 전국에 분포한다. 거풍, 화혈, 보혈, 구어혈, 조경, 진정의 효능이 있으며, 신체허약, 두통, 현운, 월경불순, 복통, 질타손상, 장조변비를 치료하며, 뿌리에는 데쿠신, 데쿠시놀, 노다케네틴, 움벨리페론, 노다케닌, 베타-시토세롤 등의 성분이 알려져 있다.(정보섭 외, 도해향약대사전, 영림당, pp 411, 1989;류경수 외, 참당귀근의 쿠마린 성분에 관한 연구, 11:33-35, 1967). Angelica Angelica gigas Nakai) is found in mountains and valleys of wetlands and is distributed throughout the country. It has the effect of swelling, chemostasis, blood, colloquial, landscaping, soothing. It treats body weakness, headache, dizziness, dysmenorrhea, abdominal pain, vaginal damage and intestinal constipation. , Titanium Valley Peron, Noda kenin, beta-cytokines are components such as are known glycerol (pp, et al., illustrates hyangyak Dictionary, Younglim per jeongboseop 411, 1989; et al ryugyeongsu, study on the coumarin component of Angelica gigas muscle, 11: 33-35, 1967) .
목단피(Moutan Cortex Radicis)는 모란(Paeonia suffruticosa)의 뿌리껍질로 뿌리에는 파에오놀(paeonol), 파에오노사이드(paeonoside), 파에오노라이드(paeonolide), 파에오니플로린(paeoniflorin)이 함유되어 있다. (정보섭 외, 도해향약대사전, 영림당, pp.526, 1989) Moutan Cortex Radicis is Paeonia a root bark of suffruticosa) roots par ohnol (paeonol), par Ono side (paeonoside), par Ono fluoride (paeonolide), par sludge may contain Florin (paeoniflorin). (Information, Dohae Hyangjeok Dictionary , Younglimdang, pp.526, 1989)
생지황(Rehmannia glutinosa Libschitz var. purpurea Makino)은 현삼과에 속하는 다년생 초본식물의 신선한 뿌리를 약재로 쓰는데, 이것을 지황이라고 한다. 신선한 근경을 생지황 또는 선지황, 말린 것을 건지황, 생지황을 황주(黃酒)에 넣고 찌고 햇볕에 말린 것을 9번 거듭한 것을 숙지황이라고도 한다. Rehmannia glutinosa Libschitz var.purpurea Makino uses fresh roots of perennial herbaceous plants belonging to the family Ginsengaceae as a medicine. Fresh root roots of fresh or seonjihwang, dried dried kohwanghwang, raw sulfur added to Hwangju (黃酒) steamed and sun dried 9 times repeated is also known as sujijihwang.
감초(甘草, Glycyrrhizae radix)는 많은 복합 처방에 빈번히 응용되는 일반적으로 안전한 한약제이다(Kamei, J., et al., Eur . J. Pharmacol ., 469, pp159-163, 2003). 다년생 초본으로 근경(根莖)은 원주상(圓柱狀)인데 주근(主根)은 매우 길고 거칠고 크며, 외피(外皮)는 적갈색에서 암갈색이다. 뿌리는 단맛이 나서 감미료, 한약재로 사용하여, 중국 동북부와 시베리아, 몽골 등지에 분포한다. 감초의 근(根)과 근경(根莖)에는 트리테르펜(triterpene) 계(系) 사포닌(saponin), 글리시르히진(glycyrrhizin)이 함유되어 있는데, 이것은 글리시르히진산의 2-글루쿠론(glucuron)산 배당체로 감초의 감미성분이다. 이 배당체에는 혈액작용은 없으나 글리시르헤틴(glycyrrhetin)산에는 있다. 감초(根)의 가수분해 성분 중에는 우랄렌(uralen)산이 추출되어 이것이 18α-글리시르헤틴 산이라는 것이 증명되었다 (정보섭 외, 도해향약대사전, 영림사, pp684-687, 1988).Licorice (甘草, Glycyrrhizae radix ) is a generally safe herbal medicine frequently applied in many combination prescriptions (Kamei, J., et al., Eur . J. Pharmacol . , 469 , pp 159-163, 2003). Perennial herbaceous root (root) is columnar, main root is very long, rough and large, the outer shell is reddish brown to dark brown. Root is sweet and is used as sweetener and herbal medicine. It is distributed in northeastern China, Siberia and Mongolia. The root and root of licorice contain triterpene system saponin and glycyrrhizin, which are 2-glucuron of glycyrrhizin acid. Acid glycoside, a sweet component of licorice. This glycoside has no blood but glycyrrhetin acid. Among the hydrolyzed constituents of licorice, uralene acid was extracted and it was proved that it was 18α-glycirrhetin acid. Dohaehyang Medicine Dictionary , Younglim History, pp684-687, 1988).
금은화(金銀花)는 인동덩굴(Lonicera japonica THUNB.)의 꽃봉오리로, 꽃 에는 루테올린, 이노시톨이 약 1%가 함유되어 있으며, 이외에 사포닌, 탄닌을 함유하고 있다 (정보섭 외, 도해향약대사전, 영림사, pp939-940, 1988).Geum is a bud of Lonicera japonica THUNB., Which contains about 1% of luteolin and inositol, and also saponins and tannins. Dohaehyang Medicine Dictionary , Younglimsa, pp939-940, 1988).
방풍 (防風, Glehnia littoralis)은 갯기름나물의 뿌리이다. 맛은 시고 달며 성질은 따뜻하다. 방풍에는 정유성분으로서 옥타놀(octanal), 노난올(nonanal), 쿠파렌(cuparene) 및 β-오데스몰(eudesmol) 등이 함유되어있다. 또한 쿠마린 및 크로멘 계열의 화합물로서 스코폴레틴 (scopoletin), 소라렌 (psoralen), 임페라토린 (imperatorin) 등이 함유되어있다. 항염증 및 진통작용을 가지고 있다고 알려져 있다(정보섭 외, 도해향약대사전, 영림사, p428, 1998).Windbreaks ( Glehnia littoralis ) are the roots of oil herb. The taste is sour and sweet, and the nature is warm. Windproof contains octanal, nonanal, cuparene and β-eudesmol as essential oils. It is also a coumarin and chromium-based compound that contains scopoletin, psoralen, imperatorin, and the like. It is known to have an anti-inflammatory and analgesic effects (jeongboseop et al., Illustrates hyangyak Dictionary, Younglim four, p428, 1998).
부평초 (Spirodela polyrrhiza (L.) SCHLEID.)에는 초산칼륨 및 염화칼륨, 옥소(沃素), 취소(臭素) 등의 물질이 함유되어 있다. 이들 다당류는 d-apiose의 풍부한 원천이다. 그 밖에 수지(樹脂), 납질(蠟質), 스테롤(sterol) 류, 엽록소, 당단백질(糖蛋白質), 점토질, 탄닌 등이 들어 있다 (정보섭 외, 도해향약대사전, 영림사, p277, 1998) Bupyeongcho ( Spirodela polyrrhiza (L.) SCHLEID.) Contains substances such as potassium acetate and potassium chloride, oxo, oval and the like. These polysaccharides are a rich source of d-apiose. Other resin (樹脂), napjil (蠟質), sterols (sterol) flow, which contains the chlorophyll, such as glycoproteins (糖蛋白質), clay, tannins (outer jeongboseop, illustrated hyangyak Dictionary, Younglim four, p277, 1998)
연교 (Forsythia koreana Nakai)는 개나리의 열매로, 과실에는 포르시톨(forsythol), 스테롤(sterol) 화합물, 사포닌(sapinin)(無溶血性(무용혈성)), 플라보놀(flavonol) 배당체류(配糖體類), 메테레시노시드(matairesinoside) 등이 함유되어 있고 과피에는 오레아놀린산(oleanolic acid)가 함유되어 있다. 靑連翹(청연교)에는 사포닌(saponin) 4.89%, 알카로이드(alkaloid) 0.2%가 함유되어 있고 필리게닌(phylligenin), 피노레시놀(pinoresinol), 바이세폭시리그난(bisepoxylignan) 등이 함유되어 있다 (정보섭 외, 도해향약대사전, 영림사, p974-975, 1998).Fellowship ( Forsythia koreana Nakai is the fruit of forsythia, and fruit includes forsythol, sterol compounds, saponins, and flavonol glycosides. ), Meteresinoside, etc., and the rind contains oleanolic acid. Cheongyeon Bridge contains 4.89% of saponin and 0.2% of alkaloid and contains phylligenin, pinoresinol, bisepoxylignan, etc. jeongboseop others, illustrate hyangyak Dictionary, Younglim four, p974-975, 1998).
적작약 (Paeonia lactiflora PALL)의 뿌리에는 파에오니플로린(paeoniflorin), 파에오놀(paeonol), 파에오닌(paeonin), 정유, 지방유, 수지, 탄닌, 당, 전분, 점액질, β-시토스테롤, 트라이데르페노이드를 함유한다 (정보섭 외, 도해향약대사전, 영림사, p523, 1998).Peony ( Paeonia The roots of lactiflora PALL contain paeoniflorin, paeonol, paeonin, essential oils, fatty oils, resins, tannins, sugars, starch, mucus, β-sitosterol and triderpenoids. (Informatics et al., Dohae Hyangjeomsa Dictionary , Younglimsa, p523, 1998).
천궁 (Cnidium officinale MAKINO)의 성분으로는 크리딜리드(cnidilide), 링구스티라이드(ligustilide), 네오크니딜리드(neocnidilide), 부틸프탈리드(butylphthalide), 세다노인산(sedanonic acid)등이 알려져 있다 (정보섭 외, 도해향약대사전, 영림사, p418, 1998). Cnidium The components of officinale MAKINO are known as cnidilide, ligustilide, neocnidilide, butylphthalide, and sedanonic acid. , Dohae Hyangjeok Dictionary , Yeonglimsa, p418, 1998).
형개 (荊芥, Schizonepeta tenuifolia var. japonica KITAGAWA)는 꿀풀과(Labiatae)에 속하는 일년생 초본의 전초를 햇볕에 말려서 사용한다. 그 성분으로는 정유 1.8%를 함유되어 있으며, 정유 중에는 d-멘톤(d-menthone), dl-멘톤(dl-menthone)과 소량의 d-리모넨(d-limonene)을 포함하고 있다. 해표(解表), 거풍(祛風), 이혈(理血)의 효능이 있다(정보섭 외, 도해향약대사전, 영림사, pp863-4, 1998).Penguin (荊芥, Schizonepeta tenuifolia var. japonica KITAGAWA uses sun-dried herbs of annual herb, belonging to Labiatae . The oil contains 1.8% of essential oils, and d-menthone, dl-menthone and a small amount of d-limonene are included in the essential oil. It has the effect of Hae-pyo, Geopung, and Bleeding (Information et al., Dohae Hyangjeomsa Dictionary , Younglimsa, pp863-4, 1998).
백강잠은 누에(Bombyx mori L.)가 토사하기 전에 백강잠균(Beauveria bassiana VUILL)의 감염에 의해 강직사한 것으로 회분 6.34%, 단백질 67.44%, 지방 4.38%, 수분 11.31%를 함유한다. 강직성 풍병을 치료하고, 풍열을 제거하는 효능이 있다 (본초학교수, 본초학 , 영림사, pp.505-506).Albino silkworm ( Bombyx mori L.) was erected by an infection with Beauveria bassiana V UILL before sedimentation and contained 6.34% ash, 67.44% protein, 4.38% fat, and 11.31% moisture. Efficacy in treating ankylosing wind diseases and removing wind fever (Professor of Herbology , Herbology , Younglim History, pp.505-506).
박하 (Mentha arvensis L. var. piperascens MALINV.)는 신선한 잎은 정유 0.8 ~ 1%를 함유한다. 유중(油中)의 주성분은 멘톨로 약 77~78%를 함유하며, 다음이 멘톤으로 8~12%를 함유한다 (정보섭 외, 도해향약대사전, 영림사, pp851-852, 1998).Mint ( Mentha arvensis L. var. piperascens MALINV.) Fresh leaves contain 0.8 to 1% essential oils. The main component of the water-in-oil (油中) contains at about 77 ~ 78% menthol, and then the containing 8-12% by menthone (jeongboseop et al., Illustrates hyangyak Dictionary, Younglim four, pp851-852, 1998).
수우각 (수우각은 물소의 뿔로서 서우각 (Rhinoceri Cornu)의 대용품으로 (박선동외, 한약처방의 구성원리, 영림사, p.127) 사용하였으며, 서우각은 량혈지혈, 사화해독의 효능이 있다 (본초학교수, 본초학 , 영림사, pp.189).Right bundle branch number (the number of right bundle branch was used as a substitute for each Nishi (Rhinoceri Cornu) (bakseondong addition, the configuration principle of the Chinese medicine prescription, Younglim four, p.127) as a horn of buffalo, Nishi angle of the efficacy of the hemostatic ryanghyeol, reconciliation decrypting (Professor of Herbology , Herbology , Younglim History, pp.189).
황금 (Scutellaria baicalensis GEORGI)의 뿌리는 베카레인(baicalein), 베카린(baicalin), 우고닌(wogonin), 우고노시드(wogonoside) 및 네오베카레인(neobaicalein)을 함유하며 다시 β-시토스테롤을 포함한다 (정보섭 외, 도해향약대사전, 영림사, pp864-865, 1998).Golden ( Scutellaria The roots of baicalensis GEORGI contain becaine, baicalin, wogonin, wogonoside and neoboicalein and again contain β-sitosterol. , Dohae Hyangjeomsa Dictionary , Younglim History, pp864-865, 1998).
이에 본 발명자들은 당귀, 목단피, 생지황, 감초, 금은화, 방풍, 부평초, 연교, 적작약, 천궁, 형개, 백강잠, 박하, 서우각 및 황금의 복합 생약 추출물의 우수한 피부염 억제효과를 활용하고, 약재의 부작용 경감을 위하여 본 발명진은 복합 생약 추출물의 피부도포법의 유용성을 입증하려고 시도하였다. 또한, 본 발명에서 복합 생약 추출물을 피부에 적용하는 국소제형으로 도포할 경우에도 Nc/Nga 마우스에서 뚜렷한 피부염 치료효과를 확인함으로써, 본 발명을 완성하게 되었다. Therefore, the present inventors utilize the excellent dermatitis inhibitory effect of the extracts of Angelica, Angelica, lichen, licorice, gold and silver, windproof, Bupyeongcho, Yeongyo, Red Peony, Cheongung, Hyeonggae, Baekja sleep, peppermint, Seowoogak and Golden Complex Herbs, In order to alleviate, the present inventors attempted to demonstrate the usefulness of the skin coating method of the complex herbal extract. In addition, in the present invention, even when applied as a topical formulation to apply the complex herbal extracts to the skin, by confirming the distinct treatment of dermatitis in Nc / Nga mice, the present invention was completed.
본 발명의 목적은 당귀, 목단피, 생지황, 감초, 금은화, 방풍, 부평초, 연교, 적작약, 천궁, 형개, 백강잠, 박하, 서우각 및 황금의 복합 생약 추출물을 유효성분으로 함유하는 피부염 질환의 예방 및 치료용 피부외용 약학조성물 및 화장료 조성물을 제공하는 것이다. An object of the present invention is the prevention of dermatitis diseases containing the extracts of Angelica sinensis, bark skin, saengjihwang, licorice, gold and silver, windproof, Bupyeongcho, Yeongyo, red peony, cheonggung, hyeonggae, Baekja sleep, peppermint, seogeak and gold complex as an active ingredient The present invention provides a therapeutic external skin pharmaceutical composition and a cosmetic composition.
상기 목적을 달성하기 위하여, 본 발명은 당귀, 목단피, 생지황, 감초, 금은화, 방풍, 부평초, 연교, 적작약, 천궁, 형개, 백강잠, 박하, 서우각 및 황금의 복합 생약 추출물을 유효성분으로 함유하는 피부염 질환의 예방 및 치료용 피부외용 약학조성물을 제공한다. In order to achieve the above object, the present invention contains the complex herbal extracts of Angelica sinensis, Mokjepi, raw jihwang, licorice, gold and silver, windproof, Bupyeongcho, Yeongyo, Red Peony, Cheongung, Hyeonggae, Baekjajam, Mint, Seoggak and Gold Provided is an external skin pharmaceutical composition for preventing and treating dermatitis diseases.
또한 본 발명은 당귀, 목단피, 생지황, 감초, 금은화, 방풍, 부평초, 연교, 적작약, 천궁, 형개, 백강잠, 박하, 서우각 및 황금의 복합 생약 추출물을 유효성분으로 함유하는 피부염 질환의 예방 및 개선용 화장료 조성물을 제공한다. In addition, the present invention prevents and improves the dermatitis disease containing the complex herbal extracts of Angelica sinensis, black bark skin, saengjihwang, licorice, gold and silver, windproof, Bupyeongcho, Yeongyo, red peony, cheonggung, hyunggae, Baekja sleep, peppermint, Seowookak and gold as an active ingredient. It provides a cosmetic composition for.
본원에서 정의되는 추출물은 정제수를 포함한 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합 용매, 헥산, 프로필렌글리콜, 부틸렌글리콜, 초산에칠, 글리세린, 바람직하게는 물로부터 가용된 추출물을 포함한다. Extracts as defined herein include water, including purified water, lower alcohols having 1 to 4 carbon atoms or mixed solvents thereof, hexane, propylene glycol, butylene glycol, ethyl acetate, glycerin, preferably extracts soluble from water. .
상기 혼합 생약 추출물의 건조 배합 중량비로는 당귀 15~50 : 목단피15~50 : 생지황 15~50 : 감초 5~30 : 금은화 5~30 : 방풍 5~30 : 부평초 5~30 : 연교 5~30 : 적작약 5~30 : 천궁 5~30 : 형개 5~30 : 백강잠 5~30 : 박하 2~10 : 서우각 2~10 : 황금 2~10의 중량비, 바람직하게는 당귀 15~16 : 목단피 15~16 : 생지황 15~16 : 감초 5~6 : 금은화 5~6 : 방풍 5~6 : 부평초 5~6 : 연교 5~6 : 적작 약 5~6 : 천궁 5~6 : 형개 5~6 : 백강잠 5~6 : 박하 2~3 : 서우각 2~3 : 황금 2~3의 중량비를 포함한다. As a dry blending weight ratio of the mixed herbal extracts Angelica 15 ~ 50: Mokpipi 15 ~ 50: Saengjihwang 15 ~ 50: Licorice 5 ~ 30: Geumeunhwa 5 ~ 30: Windproof 5 ~ 30: Bupyeongcho 5 ~ 30: Yeongyo 5-30: Jeokjak 5-30: Cheongung 5-30: hyeonggae 5-30: Baekgang sleep 5-30: mint 2-10: Seogak 2-10: weight ratio of 2-10 gold, preferably donkey 15-16: silk skin 15-16 : Saengjihwang 15 ~ 16: Licorice 5 ~ 6: Geumeunhwa 5 ~ 6: Windproof 5 ~ 6: Bupyeongcho 5 ~ 6: Yeonkyo 5 ~ 6: Jeonjak 5 ~ 6: Cheongung 5 ~ 6: Hyunggae 5 ~ 6: Baekgangjam 5 ~ 6: mint 2 ~ 3: wooge 2 ~ 3: includes the weight ratio of 2 ~ 3 gold.
상기 피부염 질환은 아토피성 피부염, 접촉성 피부염, 지루성 피부염, 피부 소양증, 주부습진, 홍피증 또는 건선으로부터 선택된 하나 이상의 질환, 바람직하게는 아토피성 피부염 또는 접촉성 피부염을 포함한다. The dermatitis disease includes at least one disease selected from atopic dermatitis, contact dermatitis, seborrheic dermatitis, skin pruritus, housewife eczema, erythematosis or psoriasis, preferably atopic dermatitis or contact dermatitis.
이하, 본 발명의 복합 생약 추출물의 수득 방법을 상세히 설명한다. Hereinafter, the method of obtaining the complex herbal extract of the present invention will be described in detail.
본 발명의 복합 생약 추출물은 생약 재료인 당귀, 목단피, 생지황, 감초, 금은화, 방풍, 부평초, 연교, 적작약, 천궁, 형개, 백강잠, 박하, 서우각 및 황금을 물로 세척하여 음건 후, 세절하여 상기 생약 재료 중량의 약 2 내지 8배, 바람직하게는 약 3 내지 4배 부피의 물로, 90 내지 100℃, 바람직하게는 100℃의 추출 온도에서 약 1시간 내지 1일, 바람직하게는 약 3시간 동안 냉침추출, 열수추출, 초음파 추출, 환류냉각 추출 등의 추출방법으로, 바람직하게는 열수추출법으로 추출한 후, 추출액을 냉각 후에 여과하고 여과액을 동결건조기로 건조하여 본 발명의 복합 생약 추출물을 얻을 수 있다. Complex herbal extract of the present invention is the herbal medicines Angelica, bark skin, raw jihwang, licorice, gold silver flower, windproof, Bupyeongcho, Yeongyo, Red Peony, Cheongung, Hyeonggae, Baeksijam, peppermint, seowookak and gold after washing the water, dry and cut the above About 2 to 8 times the weight of the herbal material, preferably about 3 to 4 times the volume of water, for about 1 to 1 day, preferably about 3 hours at an extraction temperature of 90 to 100 ℃, preferably 100 ℃ Extraction method of cold sediment extraction, hot water extraction, ultrasonic extraction, reflux cooling extraction, etc., preferably extracted by hot water extraction method, the extract is filtered after cooling and the filtrate is dried with a lyophilizer to obtain the complex herbal extract of the present invention have.
본 발명은 상기 제조방법으로 얻어지는 복합 생약 추출물을 유효성분으로 함유하는 피부염 질환의 예방 및 치료용 피부외용 약학조성물을 제공한다. The present invention provides a skin external pharmaceutical composition for the prevention and treatment of dermatitis diseases containing a complex herbal extract obtained by the above production method as an active ingredient.
본 발명의 피부염 질환의 예방 및 치료용 조성물은, 조성물 총 중량에 대하여 상기 추출물을 0.1 내지 50% 중량으로 포함한다. The composition for the prevention and treatment of dermatitis diseases of the present invention comprises the extract in an amount of 0.1 to 50% by weight based on the total weight of the composition.
본 발명의 복합 생약 추출물을 유효성분으로 함유하는 피부외용 약학조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다. The external dermal pharmaceutical composition containing the complex herbal extract of the present invention as an active ingredient may further include appropriate carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
본 발명에 따른 복합 생약 추출물을 유효성분으로 함유하는 피부외용 약학조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 외용제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있으며, 바람직하게는 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제의 피부 외용 약학 조성물을 제공한다. The external skin pharmaceutical composition containing the complex herbal extract according to the present invention as an active ingredient is in the form of external preparations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and sterile injectable solutions according to conventional methods, respectively. It may be used in a formulated formulation, and preferably provides an external skin pharmaceutical composition of a cream, gel, patch, spray, ointment, warning, lotion, linen, pasta or cataplasma.
본 발명의 복합 생약 추출물을 유효성분으로 함유하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 올리고당, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미 제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. Carriers, excipients and diluents that may be included in the composition containing the complex herbal extract of the present invention as an active ingredient include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber , Alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil have. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 복합 생약 추출물을 유효성분으로 함유하는 피부염 질환의 예방 및 치료용 조성물은 피부에 적용할 수 있는 피부 외용제 제형으로서 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제의 피부 외용제 형태의 약학조성물로 제조하여 사용할 수 있으나, 이에 한정하는 것은 아니다.The composition for the prevention and treatment of dermatitis diseases containing the complex herbal extract of the present invention as an active ingredient is a skin external preparation formulation that can be applied to the skin, such as creams, gels, patches, sprays, ointments, warning agents, lotions, lining agents It may be used as a pharmaceutical composition in the form of external preparations for skin, pasta or cataplasma, but is not limited thereto.
본 발명의 복합 생약 추출물을 유효성분으로 함유하는 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 조성물은 1일 0.0001 내지 100㎎/㎏으로, 바람직하게는 0.001 내지 10㎎/㎏으로 투여하는 것이 좋다. 외용투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. The preferred dosage of the composition containing the complex herbal extract of the present invention as an active ingredient depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the preferred effect, the composition of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg per day. Topical administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
또한, 본 발명은 상기의 제조방법으로 얻어지는 복합 생약 추출물을 유효성분으로 함유하는 피부염 질환의 예방 및 개선용 화장료 조성물을 제공한다. In addition, the present invention provides a cosmetic composition for the prevention and improvement of dermatitis diseases containing a complex herbal extract obtained by the above production method as an active ingredient.
본 발명의 복합 생약 추출물은 피부염 질환의 완화 효과를 갖는 화장품 및 세안제 등에 다양하게 이용될 수 있다. 본 조성물을 첨가할 수 있는 제품으로는, 예를 들어, 각종 크림, 로션, 스킨 등과 같은 화장품류와 클렌징, 세안제, 비누, 트리트먼트, 미용액 등이 있다. Complex herbal extract of the present invention can be used in a variety of cosmetics and facial cleansing and the like having an alleviating effect of dermatitis diseases. Examples of products to which the present composition can be added include cosmetics such as various creams, lotions, skins, and the like, cleansing agents, face washes, soaps, treatments, and essences.
본 발명의 화장료는 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 조성물을 포함한다. Cosmetics of the present invention comprises a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids and seaweed extract.
수용성 비타민으로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 비타민 B1, 비타민 B2, 비타민 B6, 피리독신, 염산피리독신, 비타민 B12, 판토텐산, 니코틴산, 니코틴산아미드, 엽산, 비타민 C, 비타민 H 등을 들 수 있으며, 그들의 염 (티아민염산염, 아스코르빈산나트륨염 등)이나 유도체 (아스코르빈산-2-인산나트륨염, 아스코르빈산-2-인산마그네슘염 등)도 본 발명에서 사용할 수 있는 수용성 비타민에 포함된다. 수용성 비타민은 미생물 변환법, 미생물의 배양물로부터의 정제법, 효소법 또는 화학 합성법 등의 통상의 방법에 의해 수득할 수 있다. The water-soluble vitamins may be any compound that can be incorporated into cosmetics, but preferably vitamin B1, vitamin B2, vitamin B6, pyridoxine, pyridoxine, vitamin B12, pantothenic acid, nicotinic acid, nicotinic acid amide, folic acid, vitamin C, vitamin H, and the like. Their salts (thiamine hydrochloride, sodium ascorbate salt, etc.) and derivatives (ascorbic acid-2-sodium phosphate salt, ascorbic acid-2-magnesium phosphate salt, etc.) may also be used in the water-soluble vitamins that can be used in the present invention. Included. The water-soluble vitamins can be obtained by conventional methods such as microbial transformation, purification from microorganism culture, enzyme or chemical synthesis.
유용성 비타민으로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 비타민 A, 카로틴, 비타민 D2, 비타민 D3, 비타민 E (d1-알파 토코페롤, d-알파 토코페롤, d-알파 토코페롤) 등을 들 수 있으며, 그들의 유도체 (팔미틴산아스코르빈, 스테아르산아스코르빈, 디팔미틴산아스코르빈, 아세트산dl-알파 토코페롤, 니코틴산dl-알파 토코페롤비타민 E, DL-판토테닐알코올, D-판토 테닐알코올, 판토테닐에틸에테르 등) 등도 본 발명에서 사용되는 유용성 비타민에 포함된다. 유용성 비타민은 미생물 변환법, 미생물의 배양물로부터의 정제법, 효소 또는 화학 합성법 등의 통상의 방법에 의해 취득할 수 있다. The oil-soluble vitamin may be any compound that can be incorporated into cosmetics, but preferably vitamin A, carotene, vitamin D2, vitamin D3, vitamin E (d1-alpha tocopherol, d-alpha tocopherol, d-alpha tocopherol), and the like. , Derivatives thereof (ascorbic palmitate, ascorbic stearate, ascorbic acid dipalmitate, dl-alpha tocopherol acetate, dl-alpha tocopherolvitamin E, DL-pantothenyl alcohol, D-pantotenyl alcohol, pantothenyl ethyl) Ethers, etc.) are also included in the oil-soluble vitamins used in the present invention. Oil-soluble vitamins can be obtained by conventional methods such as microbial transformation, purification of microorganism culture, enzyme or chemical synthesis.
고분자 펩티드로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 콜라겐, 가수 분해 콜라겐, 젤라틴, 엘라스틴, 가수 분해 엘라스틴, 케라틴 등을 들 수 있다. 고분자 펩티드는 미생물의 배양액으로부터의 정제법, 효소법 또는 화학 합성법 등의 통상의 방법에 의해 정제 취득할 수 있으며, 또는 통상 돼지나 소 등의 진피, 누에의 견섬유 등의 천연물로부터 정제하여 사용할 수 있다. The polymer peptide may be any compound as long as it can be incorporated into cosmetics. Preferably, collagen, hydrolyzed collagen, gelatin, elastin, hydrolyzed elastin, keratin, and the like can be given. Polymeric peptides can be purified and obtained by conventional methods such as purification from microbial cultures, enzymatic methods or chemical synthesis methods, or can be purified and used from natural products such as dermis and pig silk such as pigs and cattle.
고분자 다당으로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 히드록시에틸셀룰로오스, 크산탄검, 히알루론산나트륨, 콘드로이틴 황산 또는 그 염 (나트륨염 등) 등을 들 수 있다. 예를 들어, 콘드로이틴 황산 또는 그 염 등은 통상 포유동물이나 어류로부터 정제하여 사용할 수 있다. The polymer polysaccharide may be any compound as long as it can be blended into cosmetics. Preferably, hydroxyethyl cellulose, xanthan gum, sodium hyaluronate, chondroitin sulfate or a salt thereof (sodium salt, etc.) may be mentioned. For example, chondroitin sulfate or its salt, etc. can be normally purified from a mammal or fish.
스핑고 지질로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 세라미드, 피토스핑고신, 스핑고당지질 등을 들 수 있다. 스핑고 지질은 통상 포유류, 어류, 패류, 효모 또는 식물 등으로부터 통상의 방법에 의해 정제하거나 화학 합성법에 의해 취득할 수 있다. The sphingolipid may be any compound as long as it can be blended into cosmetics. Preferably, ceramide, phytosphingosine, sphingosaccharide lipid, etc. may be mentioned. Sphingo lipids can usually be purified from mammals, fish, shellfish, yeasts or plants by conventional methods or obtained by chemical synthesis.
해초 엑기스로는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 갈조 엑기스, 홍조 엑기스, 녹조 엑기스 등을 들 수 있으며, 또, 이들의 해초 엑기스로부터 정제된 칼라기난, 아르긴산, 아르긴산나트륨, 아르긴산 칼륨 등도 본 발명에서 사용되는 해초 엑기스에 포함된다. 해초 엑기스는 해초로부터 통상의 방법에 의해 정제하여 취득할 수 있다. The seaweed extract may be any compound as long as it can be blended into cosmetics. Preferably, the seaweed extract may include brown algae extract, red algae extract, green algae extract, and the like. Also, calginine, arginic acid, sodium arginate, Potassium arginate and the like are also included in the seaweed extract used in the present invention. Seaweed extract can be obtained by purification from seaweed by conventional methods.
본 발명의 화장료에는 상기 필수 성분과 더불어 필요에 따라 통상 화장료에 배합되는 다른 성분을 배합해도 된다. In addition to the said essential component, you may mix | blend the cosmetics of this invention with the other components normally mix | blended with cosmetics as needed.
이외에 첨가해도 되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있다. Other components that may be added include fats and oils, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, flavorings, Blood circulation accelerators, cooling agents, restriction agents, purified water and the like.
유지 성분으로서는 에스테르계 유지, 탄화수소계 유지, 실리콘계 유지, 불소계 유지, 동물 유지, 식물 유지 등을 들 수 있다. Examples of the fat or oil component include ester fats, hydrocarbon fats, silicone fats, fluorine fats, animal fats, and vegetable fats and oils.
에스테르계 유지로서는 트리2-에틸헥산산글리세릴, 2-에틸헥산산세틸, 미리스틴산이소프로필, 미리스틴산부틸, 팔미틴산이소프로필, 스테아르산에틸, 팔미틴산옥틸, 이소스테아르산이소세틸, 스테아르산부틸, 리놀레산에틸, 리놀레산이소프로필, 올레인산에틸, 미리스틴산이소세틸, 미리스틴산이소스테아릴, 팔미틴산이소스테아릴, 미리스틴산옥틸도데실, 이소스테아르산이소세틸, 세바신산디에틸, 아디핀산디이소프로필, 네오펜탄산이소알킬, 트리(카프릴, 카프린산)글리세릴, 트리2-에틸헥산산트리메틸롤프로판, 트리이소스테아르산트리메틸롤프로판, 테트라2-에틸헥산산펜타엘리슬리톨, 카프릴산세틸, 라우린산데실, 라우린산헥실, 미리스틴산데실, 미리스틴산미리스틸, 미리스틴산세틸, 스테아르산스테아릴, 올레인산데실, 리시노올레인산세틸, 라우린산이소스테아릴, 미리스틴산이소트리데실, 팔미틴산이 소세틸, 스테아르산옥틸, 스테아르산이소세틸, 올레인산이소데실, 올레인산옥틸도데실, 리놀레산옥틸도데실, 이소스테아르산이소프로필, 2-에틸헥산산세토스테아릴, 2-에틸헥산산스테아릴, 이소스테아르산헥실, 디옥탄산에틸렌글리콜, 디올레인산에틸렌글리콜, 디카프린산프로필렌글리콜, 디(카프릴,카프린산)프로필렌글리콜, 디카프릴산프로필렌글리콜, 디카프린산네오펜틸글리콜, 디옥탄산네오펜틸글리콜, 트리카프릴산글리세릴, 트리운데실산글리세릴, 트리이소팔미틴산글리세릴, 트리이소스테아르산글리세릴, 네오펜탄산옥틸도데실, 옥탄산이소스테아릴, 이소노난산옥틸, 네오데칸산헥실데실, 네오데칸산옥틸도데실, 이소스테아르산이소세틸, 이소스테아르산이소스테아릴, 이소스테아르산옥틸데실, 폴리글리세린올레인산에스테르, 폴리글리세린이소스테아르산에스테르, 시트르산트리이소세틸, 시트르산트리이소알킬, 시트르산트리이소옥틸, 락트산라우릴, 락트산미리스틸, 락트산세틸, 락트산옥틸데실, 시트르산트리에틸, 시트르산아세틸트리에틸, 시트르산아세틸트리부틸, 시트르산트리옥틸, 말산디이소스테아릴, 히드록시스테아르산 2-에틸헥실, 숙신산디2-에틸헥실, 아디핀산디이소부틸, 세바신산디이소프로필, 세바신산디옥틸, 스테아르산콜레스테릴, 이소스테아르산콜레스테릴, 히드록시스테아르산콜레스테릴, 올레인산콜레스테릴, 올레인산디히드로콜레스테릴, 이소스테아르산피트스테릴, 올레인산피트스테릴, 12-스테알로일히드록시스테아르산이소세틸, 12-스테알로일히드록시스테아르산스테아릴, 12-스테알로일히드록시스테아르산이소스테아릴 등의 에스테르계 등을 들 수 있다. As ester fats and oils, glyceryl tri2-ethylhexanoate, cetyl 2-ethylhexanoate, isopropyl myristate, butyl mystinate, isopropyl palmitate, ethyl stearate, octyl palmitate, isocetyl isostearate, and stearic acid Butyl, ethyl linoleate, isopropyl linoleate, ethyl oleate, isocetyl acid isocetyl, isostyl acid isostearyl, isostaryl palmitate, octylate acid octyldodecyl, isostearic acid isetyl, diethyl sebacate, adipine Acid isopropyl, isoalkyl neopentane, tri (capryl, capric acid) glyceryl, trimethyl ethyl trimethylol propane, triisostearic acid trimethylol propane, tetra 2-ethylhexanoic penta erythritol Cetyl caprylate, lauric acid decyl, hexyl laurate, decyl myristin, myristin acid myristyl, myritic acid cetyl, stearyl stearate, decyl oleate, rininooleic acid Isostearyl laurate, isotridecyl myristin, isocetyl palmitate, cetyl, octyl stearate, isocetyl stearate, isodecate oleate, octylate dodecyl oleate, octyl dodecyl, isostearic acid isopropyl, 2 -Cetostearyl ethylhexanoate, stearyl 2-ethylhexanoate, hexyl isostearate, ethylene glycol dioctanoate, ethylene glycol dioleate, propylene glycol dicapric acid, propylene glycol dicacapate, capric acid Propylene glycol, dicapric acid neopentyl glycol, dioctanoate neopentyl glycol, tricaprylic acid glyceryl, triundecyl glyceryl, triisopalmitinate glyceryl, triisostearate glyceryl, neopentane dodecyl Isostearyl octanoate, octyl isononate, hexyl decyl neodecanoate, octyl dodecyl neodecanoate, isocetyl isostearate, isostearyl isostearate, Sothete octylate, polyglycerol oleate, polyglycerine isostearate, triisocetyl citrate, triisoalkyl citrate, triisoctyl citrate, lauryl lactate, myritic lactate, octyl lactate, octyl lactate, tricitric acid Ethyl, acetyl triethyl citrate, acetyl tributyl citrate, trioctyl citrate, diisostearyl malic acid, 2-ethylhexyl hydroxystearate, di2-ethylhexyl succinate, diisobutyl adipicate, diisopropyl sebacinate, Dioctyl sebacate, cholesteryl stearate, cholesteryl isostearate, cholesteryl hydroxystearate, cholesteryl oleate, dihydrocholesteryl oleate, physteryl isostearate, phytic oleate, 12-Steloylhydroxystearate isocetyl, 12-Steloylhydroxystearate stearyl, 12-steal One hydroxy stearic acid and the like esters such as cetearyl source.
탄화 수소계 유지로서는 스쿠알렌, 유동 파라핀, 알파-올레핀올리고머, 이소파라핀, 세레신, 파라핀, 유동 이소파라핀, 폴리부덴, 마이크로크리스탈린왁스, 와셀린 등의 탄화 수소계 유지 등을 들 수 있다. Hydrocarbon-based fats and oils, such as squalene, a liquid paraffin, alpha-olefin oligomer, isoparaffin, ceresin, paraffin, a liquid isoparaffin, polybutene, microcrystal wax, and a vaseline, etc. are mentioned as a hydrocarbon-type fats and oils.
실리콘계 유지로서는 폴리메틸실리콘, 메틸페닐실리콘, 메틸시클로폴리실록산, 옥타메틸폴리실록산, 데카메틸폴리실록산, 도데카메틸시클로실록산, 디메틸실록산ㆍ메틸세틸옥시실록산 공중합체, 디메틸실록산ㆍ메틸스테알록시실록산 공중합체, 알킬 변성 실리콘유, 아미노 변성 실리콘유 등을 들 수 있다. Examples of the silicone-based oils and fats include polymethylsilicone, methylphenylsilicone, methylcyclopolysiloxane, octamethylpolysiloxane, decamethylpolysiloxane, dodecamethylcyclosiloxane, dimethylsiloxane, methylcetyloxysiloxane copolymer, dimethylsiloxane and methylsteoxysiloxane copolymer, and alkyl. Modified silicone oil, amino modified silicone oil and the like.
불소계 유지로서는 퍼플루오로폴리에테르 등을 들 수 있다. Perfluoro polyether etc. are mentioned as fluorine-based fats and oils.
동물 또는 식물 유지로서는 아보카도유, 아르몬드유, 올리브유, 참깨유, 쌀겨유, 새플라워유, 대두유, 옥수수유, 유채유, 행인(杏仁)유, 팜핵유, 팜유, 피마자유, 해바라기유, 포도종자유, 면실유, 야자유, 쿠쿠이너트유, 소맥배아유, 쌀 배아유, 시아버터, 월견초유, 마커데이미아너트유, 메도홈유, 난황유, 우지(牛脂), 마유, 밍크유, 오렌지라피유, 호호바유, 캔데리러왁스, 카르나바왁스, 액상 라놀린, 경화피마자유 등의 동물 또는 식물 유지를 들 수 있다.Animal or vegetable oils include avocado oil, almond oil, olive oil, sesame oil, rice bran oil, soybean oil, soybean oil, corn oil, rapeseed oil, almond oil, palm kernel oil, palm oil, castor oil, sunflower oil, grape seed oil. , Cottonseed oil, Palm oil, Cucumber nut oil, Wheat germ oil, Rice germ oil, Shea butter, Walnut colostrum oil, Marker demia nut oil, Meadow home oil, Egg yolk oil, Uji, Horse oil, Mink oil, Orange rape oil, Jojoba oil And animal or plant fats and oils such as candeler wax, carnava wax, liquid lanolin and hardened castor oil.
보습제로서는 수용성 저분자 보습제, 지용성 분자 보습제, 수용성 고분자, 지용성 고분자 등을 들 수 있다. Examples of the moisturizing agent include a water-soluble low molecular moisturizer, a fat-soluble molecular moisturizer, a water-soluble polymer, and a fat-soluble polymer.
수용성 저분자 보습제로서는 세린, 글루타민, 솔비톨, 만니톨, 피롤리돈-카르복실산나트륨, 글리세린, 프로필렌글리콜, 1,3-부틸렌글리콜, 에틸렌글리콜, 폴리에틸렌글리콜B(중합도 n = 2 이상), 폴리프로필렌글리콜(중합도 n = 2 이상), 폴리글리세린B(중합도 n = 2 이상), 락트산, 락트산염 등을 들 수 있다. Water-soluble low molecular humectants include serine, glutamine, sorbitol, mannitol, pyrrolidone-sodium carboxylate, glycerin, propylene glycol, 1,3-butylene glycol, ethylene glycol, polyethylene glycol B (polymerization degree n = 2 or more), polypropylene Glycol (polymerization degree n = 2 or more), polyglycerol B (polymerization degree n = 2 or more), lactic acid, lactic acid salt, etc. are mentioned.
지용성 저분자 보습제로서는 콜레스테롤, 콜레스테롤에스테르 등을 들 수 있다. Examples of the fat-soluble low molecular humectants include cholesterol and cholesterol esters.
수용성 고분자로서는 카르복시비닐폴리머, 폴리아스파라긴산염, 트라가칸트, 크산탄검, 메틸셀룰로오스, 히드록시메틸셀룰로오스, 히드록시에틸셀룰로오스, 히드록시프로필셀룰로오스, 카르복시메틸셀룰로오스, 수용성 키틴, 키토산, 덱스트린 등을 들 수 있다. Examples of the water-soluble polymer include carboxyvinyl polymer, polyasparaginate, tragacanth, xanthan gum, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, water soluble chitin, chitosan, and dextrin. Can be.
지용성 고분자로서는 폴리비닐피롤리돈ㆍ에이코센 공중합체, 폴리비닐피롤리돈ㆍ헥사데센 공중합체, 니트로셀룰로오스, 덱스트린지방산에스테르, 고분자 실리콘 등을 들 수 있다. Examples of the fat-soluble polymers include polyvinylpyrrolidone-eicosene copolymers, polyvinylpyrrolidone-hexadecene copolymers, nitrocellulose, dextrin fatty acid esters, polymer silicones, and the like.
에몰리엔트제로서는 장쇄아실글루타민산콜레스테릴에스테르, 히드록시스테아르산콜레스테릴, 12-히드록시스테아르산, 스테아르산, 로진산, 라놀린지방산콜레스테릴에스테르 등을 들 수 있다. Examples of the emollient include long-chain acyl glutamic acid cholesteryl esters, hydroxy stearic acid cholesterol, 12-hydroxystearic acid, stearic acid, rosin acid, lanolin fatty acid cholesteryl esters, and the like.
계면 활성제로서는 비이온성 계면 활성제, 음이온성 계면 활성제, 양이온성 계면 활성제, 양성 계면 활성제 등을 들 수 있다. As surfactant, nonionic surfactant, anionic surfactant, cationic surfactant, amphoteric surfactant, etc. are mentioned.
비이온성 계면 활성제로서는 자기 유화형 모노스테아르산글리세린, 프로필렌글리콜지방산에스테르, 글리세린지방산에스테르, 폴리글리세린지방산에스테르, 솔비탄지방산에스테르, POE (폴리옥시에틸렌)솔비탄지방산에스테르, POE 솔비트지방산에스테르, POE 글리세린지방산에스테르, POE 알킬에테르, POE 지방산에스테르, POE 경화피마자유, POE 피마자유, POEㆍPOP (폴리옥시에틸렌ㆍ폴리옥시프로필렌) 공중합체, POEㆍPOP 알킬에테르, 폴리에테르변성실리콘, 라우린산알카놀아미드, 알킬아민옥시드, 수소첨가대두인지질 등을 들 수 있다. As the nonionic surfactant, self-emulsifying glycerin monostearate, propylene glycol fatty acid ester, glycerin fatty acid ester, polyglycerol fatty acid ester, sorbitan fatty acid ester, POE (polyoxyethylene) sorbitan fatty acid ester, POE sorbitan fatty acid ester, POE Glycerin fatty acid ester, POE alkyl ether, POE fatty acid ester, POE hardened castor oil, POE castor oil, POE / POP (polyoxyethylene / polyoxypropylene) copolymer, POE / POP alkyl ether, polyether modified silicone, lauric acid Alkanolamide, alkylamine oxide, hydrogenated soybean phospholipid, etc. are mentioned.
음이온성 계면 활성제로서는 지방산비누, 알파-아실술폰산염, 알킬술폰산염, 알킬알릴술폰산염, 알킬나프탈렌술폰산염, 알킬황산염, POE 알킬에테르황산염, 알킬아미드황산염, 알킬인산염, POE 알킬인삼염, 알킬아미드인산염, 알킬로일알킬타우린염, N-아실아미노산염, POE 알킬에테르카르복실산염, 알킬술포숙신산염, 알킬술포아세트산나트륨, 아실화 가수분해 콜라겐펩티드염, 퍼플루오로알킬인산에스테르 등을 들 수 있다. Anionic surfactants include fatty acid soaps, alpha-acyl sulfonates, alkyl sulfonates, alkyl allyl sulfonates, alkyl naphthalene sulfonates, alkyl sulfates, POE alkyl ether sulfates, alkylamide sulfates, alkyl phosphates, POE alkylphosphates, and alkylamides. Phosphates, alkyloylalkyltaurine salts, N-acylamino acid salts, POE alkyl ether carboxylate salts, alkyl sulfosuccinate salts, sodium alkyl sulfo acetates, acylated hydrolyzed collagen peptide salts, perfluoroalkyl phosphate esters, and the like. have.
양이온성 계면 활성제로서는 염화알킬트리메틸암모늄, 염화스테아릴트리메틸암모늄, 브롬화스테아릴트리메틸암모늄, 염화세토스테아릴트리메틸암모늄, 염화디스테아릴디메틸암모늄, 염화스테아릴디메틸벤질암모늄, 브롬화베헤닐트리메틸암모늄, 염화벤잘코늄, 스테아르산디에틸아미노에틸아미드, 스테아르산디메틸아미노프로필아미드, 라놀린 유도체 제 4급 암모늄염 등을 들 수 있다. As cationic surfactant, alkyl trimethylammonium chloride, stearyl trimethyl ammonium chloride, stearyl trimethyl ammonium chloride, cetostearyl trimethyl ammonium chloride, distearyl dimethyl ammonium chloride, stearyl dimethyl benzyl ammonium bromide, behenyl trimethyl ammonium chloride, chloride Benzalkonium, diethylaminoethyl stearate, dimethylaminopropyl stearate, lanolin derivatives, quaternary ammonium salts, and the like.
양성 계면 활성제로서는 카르복시베타인형, 아미드베타인형, 술포베타인형, 히드록시술포베타인형, 아미드술포베타인형, 포스포베타인형, 아미노카르복실산염형, 이미다졸린 유도체형, 아미드아민형 등의 양성 계면 활성제 등을 들 수 있다. Examples of amphoteric surfactants include the carboxybetaine type, the amide betain type, the sulfobetain type, the hydroxysulfobetain type, the amide sulfobetain type, the phosphobetaine type, the aminocarboxylate type, the imidazoline derivative type, and the amideamine type. An amphoteric surfactant etc. are mentioned.
유기 및 무기 안료로서는 규산, 무수규산, 규산마그네슘, 탤크, 세리사이트, 마이카, 카올린, 벵갈라, 클레이, 벤토나이트, 티탄피막운모, 옥시염화비스무트, 산화지르코늄, 산화마그네슘, 산화아연, 산화티탄, 산화알루미늄, 황산칼슘, 황산바륨, 황산마그네슘, 탄산칼슘, 탄산마그네슘, 산화철, 군청, 산화크롬, 수산화크롬, 칼라민 및 이들의 복합체등의 무기 안료 ; 폴리아미드, 폴리에스테르, 폴 리프로필렌, 폴리스티렌, 폴리우레탄, 비닐수지, 요소수지, 페놀수지, 불소수지, 규소수지, 아크릴수지, 멜라민수지, 에폭시수지, 폴리카보네이트수지, 디비닐벤젠ㆍ스티렌 공중합체, 실크파우더, 셀룰로오스, CI 피그먼트옐로우, CI 피그먼트오렌지 등의 유기 안료 및 이들의 무기 안료와 유기 안료의 복합 안료 등을 들 수 있다. Organic and inorganic pigments include silicic acid, silicic anhydride, magnesium silicate, talc, sericite, mica, kaolin, bengala, clay, bentonite, titanium film mica, bismuth oxychloride, zirconium oxide, magnesium oxide, zinc oxide, titanium oxide, aluminum oxide Inorganic pigments such as calcium sulfate, barium sulfate, magnesium sulfate, calcium carbonate, magnesium carbonate, iron oxide, ultramarine blue, chromium oxide, chromium hydroxide, calamine and composites thereof; Polyamide, Polyester, Polypropylene, Polystyrene, Polyurethane, Vinyl Resin, Urea Resin, Phenolic Resin, Fluorine Resin, Silicon Resin, Acrylic Resin, Melamine Resin, Epoxy Resin, Polycarbonate Resin, Divinylbenzene / Styrene Copolymer And organic pigments such as silk powder, cellulose, CI pigment yellow, and CI pigment orange, and composite pigments of these inorganic pigments and organic pigments.
유기 분체로서는 스테아르산칼슘 등의 금속비누 ; 세틸린산아연나트륨, 라우릴린산아연, 라우릴린산칼슘 등의 알킬인산금속염 ; N-라우로일-베타-알라닌칼슘, N-라우로일-베타-알라닌아연, N-라우로일글리신칼슘 등의 아실아미노산 다가금속염; N-라우로일-타우린칼슘, N-팔미토일-타우린칼슘 등의 아미드술폰산 다가금속염; N-엡실론-라우로일-L-리진, N-엡실론-팔미토일리진, N-알파-파리토일올니틴, N-알파-라우로일아르기닌, N-알파-경화우지지방산아실아르기닌 등의 N-아실염기성아미노산 ; N-라우로일글리실글리신 등의 N-아실폴리펩티드 ; 알파-아미노카프릴산, 알파-아미노라우린산 등의 알파-아미노지방산 ; 폴리에틸렌, 폴리프로필렌, 나일론, 폴리메틸메타크릴레이트, 폴리스티렌, 디비닐벤젠ㆍ스티렌 공중합체, 사불화에틸렌 등을 들 수 있다. As organic powder, Metal soaps, such as a calcium stearate; Alkyl phosphate metal salts such as sodium cetylinate, zinc lauryl acid and calcium laurate; Acylamino acid polyvalent metal salts such as N-lauroyl-beta-alanine calcium, N-lauroyl-beta-alanine zinc, and N-lauroylglycine calcium; Amide sulfonic acid polyvalent metal salts, such as N-lauroyl-taurine calcium and N-palmitoyl-taurine calcium; N-epsilon-lauroyl-L-lysine, N-epsilon-palmitolyzine, N-alpha-paratoylol nitin, N-alpha-lauroyl arginine, N-alpha-cured fatty acid acyl arginine -Acyl basic amino acid; N-acyl polypeptides, such as N-lauroyl glycyl glycine; Alpha-amino fatty acids such as alpha-aminocaprylic acid and alpha-aminolauric acid; Polyethylene, polypropylene, nylon, polymethyl methacrylate, polystyrene, divinylbenzene-styrene copolymer, ethylene tetrafluoride and the like.
자외선 흡수제로서는 파라아미노벤조산, 파라아미노벤조산에틸, 파라아미노벤조산아밀, 파라아미노벤조산옥틸, 살리실산에틸렌글리콜, 살리신산페닐, 살리신산옥틸, 살리신산벤질, 살리신산부틸페닐, 살리신산호모멘틸, 계피산벤질, 파라메톡시계피산-2-에톡시에틸, 파라메톡시계피산옥틸, 디파라메톡시계피산모노-2-에틸헥산글리세릴, 파라메톡시계피산이소프로필, 디이소프로필ㆍ디이소프로필계피 산에스테르 혼합물, 우로카닌산, 우로카닌산에틸, 히드록시메톡시벤조페논, 히드록시메톡시벤조페논술폰산 및 그 염, 디히드록시메톡시벤조페논, 디히드록시메톡시벤조페논디술폰산나트륨, 디히드록시벤조페논, 테트라히드록시벤조페논, 4-tert-부틸-4'-메톡시디벤조일메탄, 2,4,6-트리아닐리노-p-(카르보-2'-에틸헥실-1'-옥시)-1,3,5-트리아진, 2-(2-히드록시-5-메틸페닐)벤조트리아졸 등을 들 수 있다.Examples of the ultraviolet absorber include paraaminobenzoic acid, ethyl paraaminobenzoate, amyl paraaminobenzoic acid, octyl paraaminobenzoate, ethylene glycol salicylate, phenyl salicylate, octyl salicylate, benzyl salicylate, butylphenyl salicylate, homomentyl salicylic acid and benzyl cinnamic acid. , Paramethoxy cinnamic acid-2-ethoxyethyl, paramethoxy cinnamic acid octyl, diparamethoxy cinnamic acid mono-2-ethylhexane glyceryl, paramethoxy cinnamic acid isopropyl, diisopropyl diisopropyl cinnamic acid ester mixture, Urocanoic acid, ethyl urocanate, hydroxymethoxybenzophenone, hydroxymethoxybenzophenonesulfonic acid and salts thereof, dihydroxymethoxybenzophenone, dihydroxymethoxybenzophenonedisulfonic acid sodium salt, dihydroxybenzo Phenone, tetrahydroxybenzophenone, 4- tert -butyl-4'-methoxydibenzoylmethane, 2,4,6-trianilino- p- (carbo-2'-ethylhexyl-1'-oxy)- 1,3,5-triazine, 2- (2-hi And the like can be mentioned hydroxy-5-methylphenyl) benzotriazole.
살균제로서는 히노키티올, 트리클로산, 트리클로로히드록시디페닐에테르, 크로르헥시딘글루콘산염, 페녹시에탄올, 레조르신, 이소프로필메틸페놀, 아줄렌, 살리칠산, 진크필리티온, 염화벤잘코늄, 감광소 301 호, 모노니트로과이어콜나트륨, 운데시렌산 등을 들 수 있다. As fungicides, hinokithiol, trichloric acid, trichlorohydroxydiphenyl ether, chlorhexidine gluconate, phenoxyethanol, resorcin, isopropylmethylphenol, azulene, salicylic acid, ginxitlionone, benzalkonium chloride, photosensitive Sodium No. 301, sodium mononitroguicol, undecylenic acid, and the like.
산화 방지제로서는 부틸히드록시아니솔, 갈릭산프로필, 엘리소르빈산 등을 들 수 있다. Examples of the antioxidant include butylhydroxyanisole, propyl gallic acid, and erythorbic acid.
pH 조정제로서는 시트르산, 시트르산나트륨, 말산, 말산나트륨, 프말산, 프말산나트륨, 숙신산, 숙신산나트륨, 수산화나트륨, 인산일수소나트륨 등을 들 수 있다. Examples of the pH adjuster include citric acid, sodium citrate, malic acid, sodium malate, fmaric acid, sodium pmarate, succinic acid, sodium succinate, sodium hydroxide, sodium dihydrogen phosphate, and the like.
알코올로서는 세틸알코올 등의 고급 알코올을 들 수 있다. Examples of the alcohol include higher alcohols such as cetyl alcohol.
또한, 이외에 첨가해도 되는 배합 성분은 이에 한정되는 것은 아니며, 또, 상기 어느 성분도 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 배합 가능하지만, 총중량에 대하여 바람직하게는 0.01 - 5 % 중량 백분율, 보다 바람직하게는 0.01 - 3 % 중량 백분율로 배합된다. Moreover, the compounding component which may be added other than this is not limited to this, Moreover, Although all said components can be mix | blended within the range which does not impair the objective and effect of this invention, Preferably it is 0.01-5% weight percentage with respect to a total weight, More preferably 0.01-3% by weight.
본 발명의 화장료는 용액, 유화물, 점성형 혼합물 등의 형상을 취할 수 있다. The cosmetic of the present invention may take the form of a solution, an emulsion, a viscous mixture, or the like.
본 발명의 화장료 조성물에 포함되는 성분은 유효성분으로서 상기 화합물 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예를 들면, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제 및 담체를 포함한다. Ingredients included in the cosmetic composition of the present invention may include components commonly used in cosmetic compositions in addition to the compound as an active ingredient, for example, conventional auxiliary agents such as stabilizers, solubilizers, vitamins, pigments and flavorings. And carriers.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어 유액, 크림, 화장수, 팩, 파운데이션, 로션, 미용액, 모발화장료 등을 들 수 있다. The cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, and includes, for example, milky lotion, cream, lotion, pack, foundation, lotion, essence, hair cosmetic, and the like.
구체적으로, 본 발명의 화장료 조성물은 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저의 제형을 포함한다. Specifically, the cosmetic composition of the present invention skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisturizing cream, hand cream, foundation, essence, nutrition essence, Formulations of packs, soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions and body cleansers.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다. When the formulation of the present invention is a paste, cream or gel, animal carriers, vegetable fibers, waxes, paraffins, starches, tracantes, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide, etc. may be used as carrier components. Can be.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다. When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다. When the formulation of the present invention is a solution or emulsion, a solvent, solvating or emulsifying agent is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다. When the dosage form of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline Cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다. When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, an isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide. Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
이하, 본 발명을 하기 실시예 및 실험예에 의해 상세히 설명한다. Hereinafter, the present invention will be described in detail by the following Examples and Experimental Examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 의해 한정되는 것은 아니다. However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following Examples and Experimental Examples.
실시예Example 1. 복합 생약 추출물 ( 1.Combined herbal extract ( SPSP -1)의 제조-1) Preparation
대원약업사 (대구)에서 구입하여 음건 및 잘게 분쇄한 당귀 240g, 목단피 240g, 생지황 240g, 감초 80g, 금은화 80g, 방풍 80g, 부평초 80g, 연교 80g, 적작약 80g, 천궁 80g, 형개 80g, 백강잠 80g, 박하 40g, 서우각 40g 및 황금 40g에 물 4,000 ml를 가하였고, 100℃에서 3시간 동안 열수추출하였다. 여과지(3M)를 이용하여 여과한 다음, 여액을 동결건조기 (EYELA FDU-1100)를 이용하여 감압 농축한 다음 건조하여 복합 생약 추출물 232.6g을 얻었고, 하기 실험예의 시료로 사용하였다 (이하, “SP-1"이라 명명함). Purchased from Daewon Pharmaceutical Co., Ltd. (Daegu) 240g, dried and finely pulverized donkey 240g, raw paprika 240g, licorice 80g, gold and silver flower 80g, windproof 80g, Bupyeongcho 80g, Yeongyo 80g, red pepper 80g, Cheongung 80g, 80g, Baekgangjam 80g, peppermint 4,000 ml of water was added to 40 g, 40 g of Seogwak and 40 g of gold, and hot water was extracted for 3 hours at 100 ° C. After filtration using filter paper (3M), the filtrate was concentrated under reduced pressure using a lyophilizer (EYELA FDU-1100) and dried to obtain 232.6 g of the crude herbal extract, which was used as a sample of the following experimental example (hereinafter, “SP Named -1 ").
참고예Reference Example 1. One. NCNC /Of NgaNga 피부염 마우스의 제작 Fabrication of Dermatitis Mice
NC/Nga 마우스는 자발적 아토피성 피부염 유발 모델로 잘 알려져 있다. 그 원인으로는 JAK3 kinase의 과활성으로 인한 IgE의 생성이 항진되어 나타난 결과로 보고 된 바 있으나, 현재까지도 정확한 기전은 알려져 있지 않다. 이런 기전상의 불분명성에도 불구하고 인간의 아토피성 피부염을 가장 잘 반영하는 실험모델로 약리실험에 널리 이용된다 (Matsuda et al., Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol , 9, pp.461-6, 1997). 이러한 장점에도 불구하고 자발적인 피부염 유도비율이 낮고, 유도된 피부염의 강도에도 차이가 심해 평가를 위해 신뢰할만한 모델 수준은 되지 못하고 있는 것이 사실이다. 이 문제점을 극복하기 위하여 일본에서는 합텐(hapten) 형성 물 질인 TNCB (1-chloro 2,4,6-trinitro benzene)을 이용하여 피부염을 인위적으로 유도하여 이러한 문제를 해결하고 있다. 그러나 TNCB의 경우, 국내 반입이 금지되어 이용할 수 없는 문제로 본 발명에서는 TNCB와 구조적 유사체인 DNCB(1-chloro 2,4-dinitrobenzene, 알드리치, 미국)를 이용하여 도 1에 나타낸 실험 일정으로 수행하였고 (도 1 참조), 비교적 일정한 아토피성 피부염을 유도시켰다. 본 발명에 사용된 NC/Nga 마우스는 중앙실험동물에서 구입하였으며, 5주령 웅성 마우스를 이용하였다.NC / Nga mice are well known as models for spontaneous atopic dermatitis. The cause of this was reported to be a result of IgE production due to the overactivity of JAK3 kinase, but the exact mechanism is still unknown. In spite of this mechanism ambiguity, it is the experimental model that best reflects atopic dermatitis in humans and is widely used in pharmacological experiments (Matsuda et al., Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC / Nga mice. Int Immunol , 9 , pp. 461-6, 1997). Despite these advantages, the rate of spontaneous dermatitis induction is low and the intensity of induced dermatitis is very different, making it a poor model for evaluation. In order to overcome this problem, Japan has solved this problem by artificially inducing dermatitis using TNCB (1-chloro 2,4,6-trinitro benzene), a hapten forming material. However, in the case of TNCB, domestic import is prohibited and cannot be used. In the present invention, DNCB (1-chloro 2,4-dinitrobenzene, Aldrich, USA), which is a structural analogue with TNCB, was used as the experiment schedule shown in FIG. 1. (See FIG. 1), a relatively constant atopic dermatitis was induced. NC / Nga mice used in the present invention were purchased from a central laboratory animal, and 5 week old male mice were used.
참고예Reference Example 2. 복합 생약 추출물 ( 2. Complex herbal extract ( SPSP -1)을 함유하는 피부 적용제의 제조-1) Preparation of skin applicator containing
상기 실시예 1에서 제조한 복합 생약 추출물 (SP-1)을 -80℃에서 동결 건조한 후, 피부적용을 위하여 1g, 5g 및 10gdml SP-1을 디프로필렌글리콜(dipropylen glycol) : 정제수 (1:1) 용매 100 ml에 용해시켜 각각 1%, 5%, 10%로 제조하여 상기 참고예 1의 NC/Nga 마우스에 500 microl 씩 4주간 도포하여 치료효과를 관찰하였고, 하기 실험예에서 사용하였다. After freeze-drying the composite herbal extract (SP-1) prepared in Example 1 at -80 ° C, 1g, 5g and 10gdml SP-1 was diluted with dipropylen glycol (1: 1) for skin application. 1), 5%, and 10%, respectively, were dissolved in 100 ml of solvent, and 500 microl of each was applied to the NC / Nga mouse of Reference Example 1 for 4 weeks, and the therapeutic effect was observed in the following experimental example.
실험예Experimental Example 1. 복합 생약 추출물 ( 1.Combined herbal extract ( SPSP -1)의 아토피 피부염 억제 효과 측정-1) of atopic dermatitis inhibitory effect
상기 참고예 1에서 제조한 NC/Nga 마우스에 참고예 2에서 제조한 SP-1 함유 피부 외용제를 농도별로 도포한 후, 아토피 피부염의 억제 효과를 측정하기 위해 아토피성 피부염에서 일반적으로 사용되는 임상적 육안 평가법을 이용하여 하기와 같이 실험을 수행하였다. Clinically used in atopic dermatitis in order to measure the inhibitory effect of atopic dermatitis after applying the SP-1-containing skin external preparation prepared in Reference Example 2 to the NC / Nga mouse prepared in Reference Example 1 according to the concentration. The experiment was performed as follows using the visual evaluation method.
평가 항목으로는 홍반(erythema), 가려움과 건조피부(Pruritus & Dry Skin), 부종과 혈종(Edema & escoriation), 짖무름(Erosion), 그리고 태선화(Lichenification)를 설정하여 각각의 항목은 없음(0), 약함(1), 중증도(2), 심함(3)으로 평가하였고, 최소 0점에서, 최고 15점사이의 점수를 얻을 수 있다. The evaluation items were erythema, pruritus & dry skin, edema & escoriation, erosion, and lichenification. ), Weakness (1), severity (2), and severeness (3), and scores of at least 0 and at most 15 are scored.
육안평가 결과는 상기 5가지 항목을 각각의 동물에서 평가한 후 평균점수의 총 합으로 계산하였고, 실험결과는 하기 표 1 및 도 2 내지 도 3에 나타내었다. The visual evaluation results were calculated as the total sum of the average scores after evaluating the five items in each animal, and the experimental results are shown in Table 1 and FIGS. 2 to 3.
실험결과, 상기 표 1에서 나타나는 바와 같이, SP-1 5%의 합계 점수가 1.33으로 가장 낮게 나타나 아토피 피부염 억제 효과가 뛰어남을 확인할수 있었다 (도 2 참조). As a result, as shown in Table 1, the total score of SP-1 5% was the lowest as 1.33, it was confirmed that the atopic dermatitis inhibitory effect (see Fig. 2).
또한, 피부조직은 등 주변의 환부를 중심으로 1.5 X 1.5㎠ 넓이로 절개하여 10% 포름알데히드 용액에 고정하여 조직 염색 전까지 4℃에서 보관하였다. 피부 조직은 피부의 전반적인 상태, 염증세포의 이행, 표피의 두께 등을 중심으로 관찰하였다. 이를 위해 헤마톡실린-에오신(haematoxylin-eosin) 염색을 이용하여 조직을 염색하였고, 광학현미경 상에서 100배의 배율로 병리학자에 의해 맹검실험으로 관찰, 평가하였고, 피부 조직의 표본을 도 3에 나타내었다. 도 3에서 나타나는 바와 같이, 표피에서의 가피 형성과 표피두께가 SP-1 5% 및 10% 추출물 투여시 유의성 있게 억제되는 것을 확인할 수 있었다 (도 3 참조). In addition, the skin tissue was cut in a 1.5 X 1.5 cm 2 area around the affected area around the back and fixed in 10% formaldehyde solution and stored at 4 ℃ until tissue staining. The skin tissues were observed mainly on the overall condition of the skin, migration of inflammatory cells, and epidermal thickness. To this end, tissues were stained using hematoxylin-eosin staining, and observed and evaluated by a pathologist at a magnification of 100 times on an optical microscope, and a sample of skin tissue is shown in FIG. 3. It was. As shown in FIG. 3, it was confirmed that the skin formation and epidermal thickness in the epidermis were significantly inhibited when the SP-1 5% and 10% extracts were administered (see FIG. 3).
실험예Experimental Example 2. 피부염 병리 지표를 이용한 복합 생약 추출물 ( 2. Complex herbal extract using dermatitis pathology indicator SPSP -1)의 아토피 피부염 억제 효과 측정-1) of atopic dermatitis inhibitory effect
피부염 병리 지표를 이용하여 복합 생약 추출물 (SP-1)을 농도별 처리시 아토피 피부염 억제 효과를 측정하기 위해 하기와 같이 실험을 수행하였다. In order to measure the inhibitory effect of atopic dermatitis upon concentration-specific treatment of the complex herbal extract (SP-1) using the dermatitis pathology indicator, the experiment was performed as follows.
실험군의 피부를 병리학자에게 맹검의뢰(조선대학교 의과대학 병리학교실)시 피부염 지표 변화를 도 4 내지 6에 나타내었다. 가피 형성 지표 (도 4 참조), 진피로의 염증세포 이행 정도 (도 5 참조) 및 표피두께 (도 6 참조)는 DNCB 도포로 증가하였으며, 복합 생약 추출물 (SP-1) 1, 5 및 10% 처치시 유의성 있는 억제가 관찰되었다. 그러나 농도에 따르는 차별적인 효과는 인정되지 않았다. 각 수치는 평균± 표준오차로 표시하였다. 4 to 6 shows changes in the dermatitis index when blinding the skin of the experimental group to a pathologist (Department of Pathology, Chosun University College of Medicine). The indicators of skin formation (see FIG. 4), the degree of inflammatory cell migration into the dermis (see FIG. 5) and epidermal thickness (see FIG. 6) were increased by DNCB application, and combined herbal extracts (SP-1) 1, 5 and 10% Significant inhibition was observed upon treatment. However, the differential effects of concentration were not recognized. Each figure is expressed as mean ± standard error.
실험예Experimental Example 3. 3. HaCaTHaCaT 인간 human 피부세포주에서In skin cell lines 복합 생약 추출물( Complex herbal extract ( SPSP -1)에 의한 By -1) TARCTARC mRNAmRNA 생성 억제 효과 측정 Measure generation inhibition
CC 케모카인(chemokine) 수용체 4 (CCR4)의 대표적 리간드중 하나는 TARC (thymus- and activation-regulated chemokine)이다. TARC는 Th2 세포들의 침윤에 영향을 미치며 CCR4를 경유하여 T세포 활성을 조절한다 (Imai T, et al., The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem , 272, pp.1503642,1997). One of the representative ligands of CC chemokine receptor 4 (CCR4) is thymus- and activation-regulated chemokine (TARC). TARC affects the infiltration of Th2 cells via the CCR4 regulates T cell activity (Imai T, et al., The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem , 272 , pp. 1503642,1997).
TARC는 피부 케라티노사이트(keratinocyte)에서 생성되며, Th2 세포들의 침윤을 촉진하여 피부염 진행과 악화과정에 관여한다고 알려져 있다 (Vestergaard C, et al., A Th2 Chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+ lymphocytes into lesional atopic dermatitis skin. J Invest Dermatol, 115, pp.640-6, 2000).TARC is produced in cutaneous keratinocytes and is known to be involved in dermatitis progression and exacerbation by promoting infiltration of Th2 cells (Vestergaard C, et al., A Th2 Chemokine, TARC, produced by keratinocytes may recruit CLA + CCR4 + lymphocytes into lesional atopic dermatitis skin. J Invest Dermatol, 115, pp.640-6, 2000).
따라서 복합 생약 추출물(SP-1)의 아토피 피부염 억제 효과의 가능한 기전으로 피부세포주에서 TARC mRNA 생성에 미치는 복합 생약 추출물(SP-1)의 효과를 측정하기 위해 RT-PCR 분석법으로 정량하는 실험 공정을 수행하였다 Therefore, as a possible mechanism of the atopic dermatitis inhibitory effect of the complex herbal extract (SP-1), the experimental process to quantify by the RT-PCR assay to measure the effect of the complex herbal extract (SP-1) on the production of TARC mRNA in skin cell lines Performed
총 RNA 1.0 mg을 oligo(dT) 20mer를 프라이머로 이용하여 역전사시켜 cDNA를 합성하였고, 프라이머와 반응 조건은 하기 표 5 및 표 6에 나타내었다. 1.0 mg total RNA was reverse transcribed using oligo (dT) 20mer as a primer to synthesize cDNA, and the primers and reaction conditions are shown in Tables 5 and 6 below.
이후 아가로스 겔에 전기영동하여 에티디움 브로마이드(ethidium bromide) 염색 후 밴드(band)를 확인하였다 (도 7 참조) After electrophoresis on the agarose gel, the band was confirmed after staining with ethidium bromide (see FIG. 7).
측정 결과, 도 7에서 나타나는 바와 같이, 복합 생약 추출물(SP-1)을 300 및 1000 microg/ml 농도로 세포배지에 10분간 전 처치시 염증원인 TNF-alpha/IFN-gamma (각 20 ng/ml)에 의한 TARC mRNA 생성을 인간 피부 세포주인 HaCaT 세포에서 완벽하게 차단하였다. 이는 복합 생약 추출물(SP-1)의 아토피 차단 효과가 부분적으로 케모카인 생성과정과 관련이 있음을 확인할 수 있었다. As shown in FIG. 7, TNF-alpha / IFN-gamma (20 ng / ml each) is an inflammatory source when the compound herbal extract (SP-1) was treated at 300 and 1000 microg / ml concentrations for 10 minutes before treatment. TARC mRNA production was completely blocked in HaCaT cells, a human skin cell line. This confirmed that the atopy blocking effect of the complex herbal extract (SP-1) is partially related to the chemokine production process.
본 발명의 추출물을 포함하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다. Examples of the formulation of the composition comprising the extract of the present invention will be described, but the present invention is not intended to limit it, but is intended to explain in detail only.
제제예Formulation example 1. 유연 화장수 1. Flexible Lotion
제제예Formulation example 2. 영양로션 2. Nutrition Lotion
제제예Formulation example 3. 영양크림 3. Nutrition Cream
제제예Formulation example 4. 에센스 4. Essence
제제예Formulation example 5. 친수성 연고제 5. Hydrophilic Ointment
상술한 바와 같이, 본 발명의 당귀, 목단피, 생지황, 감초, 금은화, 방풍, 부평초, 연교, 적작약, 천궁, 형개, 백강잠, 박하, 서우각 및 황금의 복합 생약 추출물을 유효성분으로 함유하는 조성물은 자발적 아토피성 피부염 유발 모델인 NC/Nga 마우스에 적용 시, 아토피 피부염 억제 및 피부세포주에서의 TARC mRNA 생성을 차단하는 효과를 확인함으로써, 피부염 질환의 예방 및 치료용 피부외용 약학조성물 및 화장료 조성물로 유용하게 이용될 수 있다. As described above, the composition containing the extracts of Angelica sinensis, bark skin, saenghwanghwang, licorice, gold and silver, windproof, Bupyeongcho, Yeongyo, Red Peony, Cheongung, Hyeonggae, Baekjap, Mint, Seogak and Gold as an active ingredient When applied to NC / Nga mice, a spontaneous atopic dermatitis induction model, by confirming the effect of inhibiting atopic dermatitis and blocking TARC mRNA production in skin cell lines, it is useful as an external skin pharmaceutical composition and cosmetic composition for the prevention and treatment of dermatitis diseases Can be used.
<110> chosun university <120> Composition comprising mixed herbal extract for preventing and treating dermatitis <160> 4 <170> KopatentIn 1.71 <210> 1 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> TARC for sense primer <400> 1 actgctccag ggatgccatc gttttt 26 <210> 2 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> TARC for anti-sense primer <400> 2 acaaggggat gggatctccc tcactg 26 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> S16 for sense primer <400> 3 tccaagggtc cgctgcagtc 20 <210> 4 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> S16 for anti-sense primer <400> 4 cgttcacctt gatgagccca tt 22 <110> chosun university <120> Composition comprising mixed herbal extract for preventing and treating dermatitis <160> 4 <170> KopatentIn 1.71 <210> 1 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> TARC for sense primer <400> 1 actgctccag ggatgccatc gttttt 26 <210> 2 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> TARC for anti-sense primer <400> 2 acaaggggat gggatctccc tcactg 26 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> S16 for sense primer <400> 3 tccaagggtc cgctgcagtc 20 <210> 4 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> S16 for anti-sense primer <400> 4 cgttcacctt gatgagccca tt 22
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020070045284A KR100881884B1 (en) | 2007-05-10 | 2007-05-10 | Composition for prevention and treatment of dermatitis disease containing complex herbal extract as an active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020070045284A KR100881884B1 (en) | 2007-05-10 | 2007-05-10 | Composition for prevention and treatment of dermatitis disease containing complex herbal extract as an active ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20080099570A true KR20080099570A (en) | 2008-11-13 |
| KR100881884B1 KR100881884B1 (en) | 2009-02-06 |
Family
ID=40286519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020070045284A Active KR100881884B1 (en) | 2007-05-10 | 2007-05-10 | Composition for prevention and treatment of dermatitis disease containing complex herbal extract as an active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100881884B1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101132833B1 (en) * | 2009-05-27 | 2012-04-02 | 조배근 | Functional patch contained reddish shale |
| WO2012043920A1 (en) * | 2010-09-28 | 2012-04-05 | 한국 한의학 연구원 | Composition for preventing or treating atopic dermatitis including galenical extract or lactobacillus fermentation thereof |
| KR101356213B1 (en) * | 2010-11-24 | 2014-01-24 | 연세대학교 원주산학협력단 | Composition for preventing or treating allergy comprising nodakenin |
| WO2015182989A1 (en) * | 2014-05-27 | 2015-12-03 | 윤종성 | Composition for prevention, treatment or improvement of skin diseases comprising cassiae semen extract and hovenia dulcis extract |
| KR20160003920A (en) * | 2014-07-01 | 2016-01-12 | 주식회사 엘지생활건강 | Cosmetic composition for anti-inflammation or improving skin trouble containing herb extracts |
| KR20160003914A (en) * | 2014-07-01 | 2016-01-12 | 주식회사 엘지생활건강 | Cosmetic composition for anti-inflammation or improving skin trouble containing herb extracts |
| WO2021201333A1 (en) * | 2020-03-31 | 2021-10-07 | 주식회사 케이피티 | Cosmetic composition for alleviating or preventing acne, containing natural extracts as active ingredients |
| CN116421531A (en) * | 2023-02-21 | 2023-07-14 | 杭州数智医济医疗科技有限公司 | Moisturizing anti-allergy skin cream and preparation method thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101189938B1 (en) | 2011-01-13 | 2012-10-12 | 대전대학교 산학협력단 | Topical Pharmaceutical Composition and cosmetic composition comprising the extract of complex herb an active ingredient for preventing and alleviating allergic or non-allergic skin disease |
| WO2012096463A2 (en) * | 2011-01-13 | 2012-07-19 | 대전대학교 산학협력단 | Composition containing a mixed herbal extract as an active ingredient for preventing and improving allergic or non-allergic skin disease, and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100272463B1 (en) * | 1998-11-16 | 2000-11-15 | 박동기 | Extract extracted from natural substance for using in cosmetics |
| KR100633380B1 (en) * | 2005-01-18 | 2006-10-20 | (주)로다멘코스메딕스 | Herbal cosmetic composition for atopic skin containing specific herbal extract mixture |
| KR20070036224A (en) * | 2005-09-29 | 2007-04-03 | 에스피엘메디코스(주) | Cosmetic composition containing complex herbal extract |
-
2007
- 2007-05-10 KR KR1020070045284A patent/KR100881884B1/en active Active
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101132833B1 (en) * | 2009-05-27 | 2012-04-02 | 조배근 | Functional patch contained reddish shale |
| WO2012043920A1 (en) * | 2010-09-28 | 2012-04-05 | 한국 한의학 연구원 | Composition for preventing or treating atopic dermatitis including galenical extract or lactobacillus fermentation thereof |
| US9295704B2 (en) | 2010-09-28 | 2016-03-29 | Korea Institute Of Oriental Medicine | Composition for preventing or treating atopic dermatitis including galenical extract or lactobacillus fermentation thereof |
| KR101356213B1 (en) * | 2010-11-24 | 2014-01-24 | 연세대학교 원주산학협력단 | Composition for preventing or treating allergy comprising nodakenin |
| WO2015182989A1 (en) * | 2014-05-27 | 2015-12-03 | 윤종성 | Composition for prevention, treatment or improvement of skin diseases comprising cassiae semen extract and hovenia dulcis extract |
| KR20160003920A (en) * | 2014-07-01 | 2016-01-12 | 주식회사 엘지생활건강 | Cosmetic composition for anti-inflammation or improving skin trouble containing herb extracts |
| KR20160003914A (en) * | 2014-07-01 | 2016-01-12 | 주식회사 엘지생활건강 | Cosmetic composition for anti-inflammation or improving skin trouble containing herb extracts |
| WO2021201333A1 (en) * | 2020-03-31 | 2021-10-07 | 주식회사 케이피티 | Cosmetic composition for alleviating or preventing acne, containing natural extracts as active ingredients |
| CN116421531A (en) * | 2023-02-21 | 2023-07-14 | 杭州数智医济医疗科技有限公司 | Moisturizing anti-allergy skin cream and preparation method thereof |
| CN116421531B (en) * | 2023-02-21 | 2024-04-09 | 杭州数智医济医疗科技有限公司 | Moisturizing anti-allergy skin cream and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100881884B1 (en) | 2009-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100881884B1 (en) | Composition for prevention and treatment of dermatitis disease containing complex herbal extract as an active ingredient | |
| KR101059471B1 (en) | Cosmetic composition for skin aging | |
| KR102883503B1 (en) | Cosmetic Uses of Protein Extract from Moringa Oleifera Seeds | |
| WO2008140200A1 (en) | External compositions for the skin | |
| KR100564108B1 (en) | Cosmetic composition containing a mixed plant extract having an anti-aging effect | |
| KR20200088074A (en) | Skin external composition comprising centella asiatica extract and papaver rhoeas extract | |
| JPH10139679A (en) | Isolation inhibitor of chemical mediator, and cosmetic, medicine and food including the same | |
| JP2003089658A (en) | Skin lotion and food excellent in anti-itchiness effectiveness | |
| KR101034405B1 (en) | Cosmetic composition for improving acne skin | |
| KR100513659B1 (en) | Cosmetic Composition for Improving Atopic Dermatitis Containing Extracts from Plants as Active Ingredient | |
| KR101799155B1 (en) | External preparation for skin comprising extract of Traditional herb | |
| KR20210018388A (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
| KR102878867B1 (en) | Composition for preventing or treating skin aging or dermatitis comprising extracts of cinnamon, honeysuckle, fragrant oil, Schisandra chinensis, Ubangja, and peony bark, and method using the same | |
| KR100776346B1 (en) | Composition with anti-dandruff, anti-inflammatory activity, containing nasturtium, succinate, sewage, and half-mixed herbal extract | |
| KR102142461B1 (en) | Composition for improving skin condition comprising extract of korean fir | |
| KR101435679B1 (en) | Composition for moisturizing and improving wrinkle on skin | |
| KR100574233B1 (en) | Cosmetic composition containing plant extracts having skin moisturizing and anti-irritant effects | |
| KR102374382B1 (en) | topical composition comprising the extract of combined herbs comprising Longanae Arillus for TSLP inhibition and for the treatment or alleviation of skin inflammatory disease | |
| KR100769302B1 (en) | Skin external composition having the effect of treating and improving wound healing and skin pruritus containing herbal extract | |
| KR20060074038A (en) | Composition having a prophylactic effect of atopic dermatitis | |
| CN117482133A (en) | Novel cosmetic or dermatological uses of Genidiflora rhizome extract | |
| KR102073837B1 (en) | A specific preparation method for preparing a distilled extract comprising extract of Schisandra chinensis and the composition comprising the same | |
| KR100644086B1 (en) | Method of manufacturing herbal baths without skin irritation | |
| KR100614465B1 (en) | Cosmetic composition having skin elasticity enhancement and anti-inflammatory effect, containing Yu-Geun Skin, Lily, Half, Pear and Pear Extract | |
| KR102790058B1 (en) | Composition for preventing, ameliorating or treating rosacea comprising Artemisia sp. plant extracts as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20070510 |
|
| PA0201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20080916 Patent event code: PE09021S01D |
|
| PG1501 | Laying open of application | ||
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20090123 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20090129 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20090129 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20111205 Start annual number: 4 End annual number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20130103 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130103 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20140521 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140521 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20151105 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20151105 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20171110 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20171110 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20181213 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20181213 Start annual number: 11 End annual number: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20201111 Start annual number: 13 End annual number: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20211111 Start annual number: 14 End annual number: 14 |
|
| PR1001 | Payment of annual fee |
Payment date: 20221114 Start annual number: 15 End annual number: 15 |
|
| PR1001 | Payment of annual fee |
Payment date: 20231108 Start annual number: 16 End annual number: 16 |
|
| PR1001 | Payment of annual fee |
Payment date: 20241111 Start annual number: 17 End annual number: 17 |